Podcasts about beyond type

It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: A new Austrailian study aims to prevent type 1, the new twiist pump will integrate with Eversnse CGM as well as Libre, diabetes deaths are down in the US, Dexcom U is looking for college athletes, and more! Find out more about Moms' Night Out  Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom   Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links: Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX A world-first human trial of a drug designed to treat the underlying cause of type 1 diabetes has begun in Australia. University of Queensland researcher Ranjeny Thomas said the experimental drug — dubbed ASITI-201 — was designed to retrain the immune system so it no longer attacks the insulin-producing pancreatic cells, known as beta cells. The drug, given as an injection under the skin, combines fragments of a protein found in the beta cells of people with type 1 diabetes and vitamin D to calm the immune response. She said if effective, the drug would initially be given to patients with type 1 diabetes as soon as possible after diagnosis to preserve remaining pancreatic cells and reduce the amount of insulin needed. But eventually, if screening programs can be developed to pick up people at risk of developing type 1 diabetes, it may be possible to "prevent the progression of the disease altogether". The first in-human trial of 36 participants will test the safety of the drug, but blood tests will also determine the impact of the therapy on a patient's immune system and glucose tolerance. https://www.abc.net.au/news/2025-04-29/type-1-diabetes-drug-trial-auto-immune-disease-science/105223022 XX   Diabetes deaths in the U.S. have fallen to some of the lowest rates in years, according to new preliminary figures published by the Centers for Disease Control and Prevention, reversing a surge in mortality that was seen during the COVID-19 pandemic.   There were 26.4 deaths per 100,000 people from diabetes, according to early death certificate data for the third quarter of 2024 published this month by the CDC's National Center for Health Statistics.   Death rates from diabetes peaked in 2021, according to CDC figures, at 31.1 deaths per 100,000 people for that year. Diabetes was the eighth leading cause of death in 2021. The CDC says the link between COVID-19 and diabetes may be to blame for that increase.   "Data show an increase in mortality rates for all people during the COVID-19 pandemic, and research shows that people with underlying conditions, including diabetes, are more likely to become very sick from COVID-19 and have a higher risk of hospitalization and death," Christopher Holliday, head of the CDC's Division of Diabetes Translation, told CBS News in a statement.   Holliday added that research shows the pandemic may also have made it harder for Americans to properly manage the disease, ranging from interruptions to physical activity to disruptions to routine medical care diagnosing and treating the disease.   https://www.cbsnews.com/news/diabetes-deaths-lowest-levels-years-early-cdc-figures/ XX Big news for the Eversense CGM – they have their first pump partner. Sequel Med Tech says the twist pump will integrate with Senseonics Eversense 365 continuous glucose monitor (CGM). This collaboration would make twiist the first AID system compatible with Eversense 365, the world's first and only one-year CGM. Sequel and Senseonics say they have already started their work to integrate the latest-generation, 365-day implantable sensor with twiist. They expect to make the integrated offering available in the third quarter of this year. This marks the second CGM integration for Sequel, which partnered with Abbott and its FreeStyle Libre platform earlier this year. This week we also got a peek at the packaging and delivery of the twist as the first people posted about wearing it. We'll follow up and learn more about this newest insulin pump in the us. Senseonics, meanwhile, brought the first year-long CGM to market last year, launching Eversense 365 with its global distribution partner, Ascensia Diabetes Care, in October 2024. The system also received clearance as an integrated CGM (iCGM) system, meaning it can work with compatible medical devices. Those include insulin pumps as part of automated insulin delivery systems. https://www.drugdeliverybusiness.com/sequel-senseonics-integrate-cgm-insulin-pump/ XX Medtronic has announced the U.S. Food and Drug Administration (FDA) approval for the Simplera Sync sensor for use with the MiniMed 780G system. With this approval, the MiniMed 780G system now offers more flexibility for users of the company's most advanced insulin delivery system featuring Meal Detection technology with both the Guardian 4 sensor and Simplera Sync sensor.   The Simplera Sync is a disposable, all-in-one sensor that requires no fingersticks with SmartGuard or overtape and features a simple, two-step insertion process. It is the company's newest addition to its CGM portfolio, which expands options and provides greater flexibility for users.   The MiniMed 780G system's adaptive algorithm automatically anticipates, adjusts, and corrects glucose levels every 5 minutes, 24/7 – working around the clock so users can focus on what matters. It's the only system featuring Meal Detection technology, which detects rising sugar levels and delivers more insulin as needed to help users keep glucose levels in range more often – even when users occasionally forget to dose insulin for snacks or meals or underestimate their carbs.   The system uses a “treat to target” approach and flexible glucose targets as low as 100 mg/dL, which, combined with its adaptive algorithm allows it to more closely mirror the glucose levels of someone not living with diabetes.   Real-world data of the system shows global users consistently achieve time in range above international targets of 70% when using optimal settings (active insulin time of two hours and 100 mg/dL target glucose). It is also the only system that works with the world's only infusion set that lasts up to 7 days so that users only have to change their infusion set once per week and can experience 96% fewer injections compared to multiple daily injections.   “We're committed to driving innovation that makes life easier for those living with diabetes so they can forget about their diabetes as much as possible throughout the day,” said Que Dallara, EVP and president of Medtronic Diabetes. “Our MiniMed 780G system delivers advanced diabetes technology for so many around the world, and we're excited to continue evolving this experience with expanded CGM options —including our Simplera Sync sensor, which we look forward to bringing to people living with diabetes in the U.S.”   A limited launch of the Simplera Sync sensor will begin in the U.S. in the fall of 2025. Today, the MiniMed 780G system can be used with the Guardian 4 sensor.   Like this:https://med-techinsights.com/2025/04/29/simplera-sync-sensor-for-minimed-780g-now-fda-approved/ XX Front office changes at Insulet.. The former head of Johnson & Johnson's worldwide medtech business, Ashley McEvoy will take over as president and CEO from Jim Hollingshead, who has led Insulet since 2022. In its announcement of the leadership change, Insulet said that Hollingshead and the company mutually agreed to part ways, effective immediately. McEvoy served as worldwide medtech chairman at J&J from 2018 until her departure in late 2023, the culmination of nearly 30 years at the company and several executive roles—including president of its Ethicon division and group chairman of vision and diabetes care. Since then, she has also served as a board member at Procter & Gamble. https://www.fiercebiotech.com/medtech/insulet-taps-former-jj-medtech-head-ashley-mcevoy-be-ceo XX New free mobile game launched this week to make type 1 diabetes onboarding faster easier and less overwhelming. It's called Level One.. created by Level Ex (Powered by Relevate Health), the studio behind award-winning medical games for medical professionals. Level Ex CEO Sam Glassenberg created the game after a – quote  - brutal onboarding experience when his daughter was diagnosed five years ago He says  It took a year to understand how to manage this disease. So we fixed it. We built a game that can train your brain to do it in a matter of hours." The game is launching in partnership with leading diabetes organizations Beyond Type 1 and Breakthrough T1D Play, who are integrating Level One into their outreach and educational campaigns to support newly diagnosed families worldwide. Download Level One on the App Store: https://apps.apple.com/us/app/level-one-a-diabetes-game/id6739605694 Learn more: https://playlevelone.com   https://www.prnewswire.com/news-releases/level-ex-launches-level-one-a-free-mobile-game-to-redefine-type-1-diabetes-onboarding-302440929.html XX   Collagen is widely recognized for its role in maintaining healthy skin, but its importance extends far beyond that. As the most abundant protein in the human body, collagen provides essential structure and support to nearly all tissues and organs.   Now, researchers at Carnegie Mellon's Feinberg Lab have made a major breakthrough using their novel Freeform Reversible Embedding of Suspended Hydrogels (FRESH) 3D bioprinting technique. This method enables the precise printing of soft, living cells and tissues. Leveraging this technology, the team successfully created the first-ever microphysiologic system, also known as a tissue model, constructed entirely from collagen. This advancement opens new possibilities for studying disease and engineering tissue therapies, including potential treatments for conditions like Type 1 diabetes.   Traditionally, small-scale models of human tissue, referred to as microfluidics, organ-on-chip devices, or microphysiologic systems, have been fabricated using synthetic materials such as silicone rubber or plastics. These materials were necessary due to limitations in earlier manufacturing techniques. However, because they are not biologically native, they fail to fully replicate natural tissue environments, restricting their effectiveness in biomedical research and therapeutic development.   “Now, we can build microfluidic systems in the Petri dish entirely out of collagen, cells, and other proteins, with unprecedented structural resolution and fidelity,” explained Adam Feinberg, a professor of biomedical engineering and materials science & engineering at Carnegie Mellon University. “Most importantly, these models are fully biologic, which means cells function better.”   Building Complex Tissues with FRESH Bioprinting In new research published in Science Advances, the group demonstrates the use of this FRESH bioprinting advancement, building more complex vascularized tissues out of fully biologic materials, to create a pancreatic-like tissue that could potentially be used in the future to treat Type 1 diabetes. This advancement in FRESH bioprinting builds on the team's earlier work published in Science, by improving the resolution and quality to create fluidic channels that are like blood vessels down to about 100-micron diameter.   “There were several key technical developments to the FRESH printing technology that enabled this work,” described Daniel Shiwarski, assistant professor of bioengineering at the University of Pittsburgh and prior postdoctoral fellow in the Feinberg lab. “By implementing a single-step bioprinting fabrication process, we manufactured collagen-based perfusable CHIPS in a wide range of designs that exceed the resolution and printed fidelity of any other known bioprinting approach to date. Further, when combined with multi-material 3D bioprinting of ECM proteins, growth factors, and cell-laden bioinks and integration into a custom bioreactor platform, we were able to create a centimeter-scale pancreatic-like tissue construct capable of producing glucose-stimulated insulin release exceeding current organoid based approaches.” https://scitechdaily.com/scientists-bioprint-living-tissues-that-could-revolutionize-diabetes-treatment/ XX Another study showing the blood sugar benefit of walking after a meal. Skeletal muscle plays a central role in glucose uptake. Exercise stimulates glucose transport into muscle cells through insulin-independent pathways, notably through the action of glucose transporter type 4 (GLUT-4), which is responsible for transporting glucose from blood to skeletal muscles.4 This means that even without a robust insulin response, physical activity can facilitate glucose clearance from the bloodstream. These effects also occur without requiring high-intensity exercise, making postprandial walking accessible to a broad range of individuals, including those with limited exercise tolerance. multiple studies show that starting activity within 30 minutes after a meal is optimal. https://www.news-medical.net/health/Walking-After-Meals-Small-Habit-Big-Metabolic-Gains.aspx XX Dexcom brings back Dexcom U for a 4th years. This is a name, image and license program for college athletes with diabetes and includes a nationwide open call for passionate and inspiring college athletes to join its roster. Now through May 23, athletes, coaches, friends and family members can nominate candidates through an online submission. Those selected, along with the eight returning athletes from last year, will be invited to attend the Dexcom U Signing Day Camp this summer, hosted by Dexcom Warrior and Baltimore Ravens tight end Mark Andrews. https://www.hmenews.com/article/dexcom-u-returns-for-fourth-season

In this episode, we dive into the mental and social toll of living with type 1 diabetes, exploring the feelings of stigma, shame, and constant need for explanation that often accompany the condition. Joining me is my friend Jake Giles, who has lived with T1D since age 16 and wrote a powerful piece for Beyond Type 1 about the isolation and embarrassment that can come with managing diabetes in social situations. Together, we discuss our shared experiences navigating diabetes, acceptance as gay men, and how the highs and lows of the condition can disrupt life's most meaningful moments. This heartfelt conversation brought me to tears, and I hope it resonates with others facing similar challenges.   Read Jake's Blog Post   Learn about Omnipod 5 (today's sponsor)*   T1D Exchange Registry Sign up  (US only)   Read our Blog + Join the Newsletter    Support Diabetech on Patreon  | Diabetech Community Discord   Follow me here: Instagram | Tik Tok | YouTube | Facebook   Watch the Podcast on Youtube   DISCLAIMERS: This podcast is not medical advice and is for educational purposes only. Always consult with your doctor before making changes to your health care.   *10-day trial eligibility may vary. Full terms and conditions apply. Visit omnipod.com/diabetech for clinical disclaimers, terms and important safety information. The Pod has an IP28 rating for up to 25 feet for 60 minutes. The Omnipod 5 Controller is not waterproof.

On today's show, we are focusing on diabetes awareness with Brittany Dement, an advocate for Beyond Type 1. Beyond Type 1 was founded in 2015 by Nick Jonas, Juliet de Baubigny, Sarah Lucas + Sam Talbot with a focus on education, advocacy and the path to a cure for Type 1 diabetes. Through platforms, programs, resources, and grants, Beyond Type 1 is uniting the global diabetes community and providing solutions to improve lives today. A new model of philanthropy, Beyond Type 1 aims to change what it means to live with chronic illness.

The concept and practice of screening for type 1 diabetes has changed significantly in the last decade. It used to be something you might have heard about at diabetes camp or a conference and weren't quite sure what to do with the information. But now, you can get actionable results with the approval of Tzield and potential development of other prevention treatments. But what do people with diabetes actually think about screening? Beyond Type 1 asked.. you answered.. and we're talking about it. Full info on the screening survey here This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Join us at an upcoming Moms' Night Out event! Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom  Edgepark Medical Supplies Check out VIVI Cap to protect your insulin from extreme temperatures Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.

It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: World Diabetes Day roundup, existing drugs examined for T1D prevention, Blue Circle Health expands its novel T1D care model, Mounjaro studied further, Canada approves a new pumps system, and tragedy in the diabetes community.  Find out more about Moms' Night Out  Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom  Edgepark Medical Supplies Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens  Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links:   Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX Of course, World Diabetes Day was yesterday. November 14 marks the birthday of Sir Frederick Banting. who discovered insulin along with Charles Best in 1922. Lots of the tech companies are taking action.. I'm going to link up a great article highlighting what many of them are doing…. from Medtronics Blue Balloon challenge to Dexcom's Nick Jonas video and a lot more. https://www.drugdeliverybusiness.com/world-diabetes-day-2024/ XX A new triple combo therapy could restore insulin production in people with type 1 using existing medications. Levicure's triple-combo oral therapy is already considered very safe, because it involves two drugs approved by the U.S. Food and Drug Administration (FDA) and a well-known supplement. The therapy is a combination of: DPP4-inhibitors, a common type 2 diabetes medication Proton pump inhibitors (PPIs), a drug for severe acid reflux A proprietary version of gamma-aminobutyric acid (GABA), a supplement often used to treat anxiety Levicure says the combined effect can block beta cell destruction, suppress autoimmunity, and restore beta cell function. So far, Levicure's triple therapy has gone through only one retrospective chart review; it has not been put to the test in a randomized controlled trial https://www.diabetesdaily.com/blog/can-this-triple-combo-oral-therapy-restore-insulin-production-733261/   XX Blue Circle Health is expanding it's unique approach to type 1 care. Already active in Florida, Maine & Vermont, it will now be in Delaware and Ohio. Blue Circle Health is free and develops a personalized care plan for each participant, tailored to their unique needs, and offers comprehensive multidisciplinary support over a six-month period. It's paid for by the Helmsley Charitable Trust. The program is available to people 18 years of age and older that speak Spanish or English, regardless of insurance coverage or citizen status. We've got an upcoming podcast episode all about Blue Circle coming up soon. https://www.prnewswire.com/news-releases/blue-circle-health-expands-to-delaware-and-ohio-to-address-health-system-barriers-to-type-1-diabetes-care-and-education-302304170.html XX An international team of experts has created the world's first evidence-based guide for eating lower and low carb. The group says until now, people with type 1 diabetes and their healthcare providers have lacked comprehensive resources to help implement this approach safely and effectively. The guide provides essential information for dietitians and nutritionists and empowers them to work collaboratively with individuals and families who are interested in reducing carbohydrates. It's free and we've got the download link in the show notes. https://www.newswire.ca/news-releases/international-team-launches-first-guide-for-carbohydrate-reduction-in-type-1-diabetes-883729104.html XX A new pump system is available in Canada. mylife YpsoPump insulin pump and CamAPS FX hybrid closed-loop algorithm by Health Canada. mylife Loop consists of the mylife YpsoPump, a lightweight intuitive insulin pump, integrated with the CamAPS FX hybrid closed-loop, a mobile phone-based algorithm, and the Dexcom G6 Continuous Glucose Monitoring (CGM) System. Working together, these components provide an innovative, automated insulin delivery (AID) system designed to simplify insulin therapy and improve glycemic control for Canadians living with diabetes.   "The approval of the mylife YpsoPump and CamAPS FX marks an important milestone as we bring these advanced technologies to the Canadian market," said Sébastien Delarive, Chief Business Officer of Ypsomed Diabetes Care. "Although Ypsomed is relatively new in Canada, our established leadership in diabetes care throughout Europe provides a solid foundation for delivering innovative solutions to Canadians living with type 1 diabetes."   "We are excited to see both mylife YpsoPump and CamAPS FX approved," said Karina Schneider, General Manager at Ypsomed Canada. "This step brings us closer to offering an integrated solution that will help simplify diabetes management for Canadian patients, empowering them to take more control of their health." https://finance.yahoo.com/news/ypsomed-camdiab-receive-health-canada-205500840.html XX The FDA updates the labels for all GLP-1 receptor agonists with a warning about pulmonary aspiration during general anesthesia or deep sedation. The affected drugs are semaglutide (Ozempic, Rybelsus, Wegovy); liraglutide (Saxenda, Victoza); and the dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 tirzepatide (Mounjaro, Zepbound). the Medication Guide section of the label also has new additions. Patients are counseled to tell their healthcare provider if they are scheduled to have surgery or other procedures that use anesthesia or deep sleepiness (deep sedation). They are alerted that the GLP-1 RAs they are taking may cause serious side effects, including food or liquid getting into the lungs during surgery or other procedures that use anesthesia or deep sedation. Patients are advised to tell all their healthcare providers that they are taking a GLP-1 RA before they are scheduled to have surgery or other procedures. https://www.medscape.com/viewarticle/fda-updates-glp-1-label-pulmonary-aspiration-warning-2024a1000k84?form=fpf XX Following an impressive data drop this summer highlighting the potential for Eli Lilly's tirzepatide to stave off progression to Type 2 diabetes in prediabetic patients, the Indianapolis-based drugmaker is laying out full results from its longest completed study of the dual GIP/GLP-1 receptor agonist to date. In the three-year SURMOUNT-1 trial, tirzepatide curbed the risk of disease progression to Type 2 diabetes by 94% versus placebo in adult prediabetes patients who were obese or overweight, Lilly said in a release Wednesday. The number represents a pooled result from three tirzepatide doses (5 mg, 10 mg and 15 mg) studied in the trial.   Putting those results into perspective, one new case of diabetes could be prevented for every nine patients treated with tirzepatide, which is marketed in the U.S. as Mounjaro for Type 2 diabetes and as Zepbound for obesity, Lilly said. https://www.fiercepharma.com/pharma/lilly-unwraps-detailed-data-showing-tirzepatide-kept-nearly-99-pre-diabetic-patients XX Edgparke commeical? XX https://www.bloomberg.com/news/articles/2024-10-25/apple-secretly-tests-blood-sugar-app-in-sign-of-health-ambitions XX XX And finally, many of you have likely already heard but we had some incredibly tragic news in the diabetes community, especially for the Breakthrough T1D ride community. I'm going to read from the Breakthrough T1D website: The leadership, staff, and volunteers of Breakthrough T1D mourn the tragic, sudden loss of five T1D Champions on Friday, Nov. 1, 2024.  Jeff and Michelle Bauer, Josh and Tammy Stahl and Barry Sievers were all killed in a singe car crash. The group included two married couples and one single individual—all very close friends and veteran Breakthrough T1D Ride participants. Of this incredibly impactful group, I knew Michelle Bauer personally, I met her as Michelle Alswager – you may know her as Jesse's mom. Her son, Jesse died from complications of type 1 in 2010. And that year, mile 23 on the JDRF ride was created as a mile of silence in memory of Jesse.  Now all riders are asked to ride in silence for that mile not only in memory of Jesse, but all those lost to type 1 diabetes. Michelle wrote her book, Jesse Was Here and created a program that's part of Beyond Type 1 to this day, all to help other families going through grief. She called me a few years ago when she was thinking of writing her book and I'm so grateful for our conversations and that our conversations may have helped her get it out there into a world where it's so needed. But we need Michelle here to talk about grief. More about talking to Michelle about the book).   Please, write the book, ride the bike, do the ironman, follow your heart and your dreams.  All of these incredible people gone too soon. https://www.breakthrought1d.org/news-and-updates/breakthrough-t1d-mourns-tragic-sudden-loss-of-five-ride-champions/   Thanks for joining me..

Welcome to the show, Xander Wells! A Mason local participating in the TCS NYC Marathon with Beyond Type 1. Xander's journey, from embracing an active lifestyle to navigating the challenges of Type 1 Diabetes, is both compelling and inspirational. His commitment to using his running journey to empower others truly sets him apart.On the Sidelines is presented by OrthoCincy Orthopaedics & Sports Medicine. Learn more about your ad choices. Visit podcastchoices.com/adchoicesSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Welcome to the show, Xander Wells! A Mason local participating in the TCS NYC Marathon with Beyond Type 1. Xander's journey, from embracing an active lifestyle to navigating the challenges of Type 1 Diabetes, is both compelling and inspirational. His commitment to using his running journey to empower others truly sets him apart. On the Sidelines is presented by OrthoCincy Orthopaedics & Sports Medicine. Learn more about your ad choices. Visit podcastchoices.com/adchoices

Nate Checketts is the Co-Founder & CEO of Rhone, a performance lifestyle brand founded in 2014. Prior to Rhone, Nate worked for and consulted with some of the biggest tech and entertainment properties in the world including Cisco, The NFL, Legends, FanVision and Sport Radar. Nate is an avid entrepreneur who founded 4 companies before the age of 30. In 2020 Nate was selected by the Sports Business Journal to their 2020 list of Forty leaders under Forty. In addition to Rhone, Nate also serves as Chairman of the Board to Beyond Type 1, a non-profit dedicated to the community of those with Type 1 Diabetes founded by Nick Jonas. Nate also serves as a Director to Clean Simple Eats, a leading brand of functional foods and recipes.   Interviewed by Kate Doerge.

It's In the News! A look at the top diabetes stories and headlines happening now. Top stories this week: The FTC sues PBMs over insulin pricing, a new CGM is approved in Europe, more news about GLP-1s but some research says it may not work as well for one population, diabetes camps are invited to apply for grants, and more! Find out more about Moms' Night Out  Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom  Edgepark Medical Supplies Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens  Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links: Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX The U.S. Federal Trade Commission sued the country's three largest pharmacy benefit managers on Friday, accusing them of steering diabetes patients towards higher priced insulin in order to reap millions of dollars in rebates from pharmaceutical companies. The case accuses UnitedHealth Group Inc's (UNH.N), opens new tab Optum unit, CVS Health Corp's (CVS.N), opens new tab CVS Caremark and Cigna Corp's (CI.N), opens new tab Express Scripts of unfairly excluding lower cost insulin products from lists of drugs covered by insurers. The three companies said in statements that the suit was baseless and defended their business practices, saying that they had lowered insulin prices for businesses, unions and patients. https://www.reuters.com/business/healthcare-pharmaceuticals/us-ftc-sues-drug-gatekeepers-over-high-insulin-prices-2024-09-20/ XX A new study finds metformin, may slow aging. Previous studies on "lower order" species have found that it can delay the onset of age-related diseases.  Gotta say, this is only in animal studies right now, not people, human trials are next. https://www.cbsnews.com/boston/news/diabetes-drug-metformin-aging/ XX New research from the Case Western Reserve University School of Medicine identifies a potential new approach to address the opioid overdose epidemic—which has devastated families and communities nationally.   The study, published in the journal JAMA Network Open, suggests semaglutide is linked to lower opioid overdoses in people with opioid-use disorder (OUD) and type 2 diabetes (T2D).   Semaglutide, a glucagon-like peptide receptor (GLP-1R) molecule that decreases hunger and helps regulate blood sugar in T2D, is also the active component in the diabetes and weight-loss drugs Wegovy and Ozempic.   The research team—led by biomedical informatics professor Rong Xu—analyzed six years of electronic records of nearly 33,000 patients with OUD who also had T2D. The researchers used a statistical approach that mimics a randomized clinical trial.   They found patients prescribed semaglutide had a significantly lower risk for opioid overdose, compared to those who had taken any of eight other anti-diabetic medications, including other types of GLP-1R-targeting medications.   About 107,500 people died from drug overdoses nationally in 2023, mostly from opioids, according to the CDC. Despite effective medications to prevent overdoses from OUD, the CDC estimates only a quarter of those with OUD receive them and about half discontinue treatment within six months. https://medicalxpress.com/news/2024-09-popular-diabetes-weight-loss-drug.html XX New research analyzing the effects of two drugs used to treat type 2 diabetes indicates a consistent lack of cardiovascular and renal benefits in Black populations. The drugs, called sodium-glucose co-transporter 2 inhibitors (SGLT2-Is) and glucogen-like peptide 1 receptor agonists (GLP1-RAs), are some of the newer treatments prescribed to lower blood sugar levels in people with type 2 diabetes. The research findings, published in the Journal of the Royal Society of Medicine, show that for White and Asian populations, SGLT2-Is and GLP1-RAs have beneficial effects on blood pressure, weight control and renal function, and significantly reduce the risk of severe heart problems and kidney disease. However, the research shows no evidence of these beneficial effects in Black populations. ""Whether the differences are due to issues with under-representation of Black populations and low statistical power, or to racial/ethnic variations in the way the body and these drugs interact with each other needs further investigation," said Professor Seidu. "It is therefore important that prescribers don't hasten to deny these newer treatments to Black populations on the back of this research." https://www.news-medical.net/news/20240923/Research-reveals-disparities-in-diabetes-drug-efficacy-for-Black-populations.aspx XX If a woman is already in a "prediabetic" state in her teen or college years, her odds for a serious complication of pregnancy later in life rises, new research shows.   Ignoring prediabetes in teenagers "may represent a missed opportunity to avert pregnancy-related complications" later, said study lead author Katharine McCarthy. She's an assistant professor of population health science and policy, and obstetrics, gynecology and reproductive science at the Icahn School of Medicine at Mount Sinai in New York City.   Her team published its findings Sept. 24 in the journal JAMA Network Open. Prior research has found that rates of prediabetes have tripled among Americans ages 12 to 19 over the past decade. In the new study, the Mount Sinai team tracked rates of prediabetes (using blood sugar tests) among a group of 14,000 New York City residents ages 10 to 24. None of these individuals had full-blown diabetes at the time they were tested.   Having prediabetes in youth was linked to a doubling of risk of gestational diabetes -- new-onset diabetes while pregnant. Tracking blood levels of hemoglobin A1c, a measure of a person's average blood sugar level over the prior three months, was very predictive of whether or a not a woman would get gestational diabetes, the team found.   Prediabetes in youth was also linked to an 18% rise in the risk for hypertensive disorders during pregnancy, such as gestational hypertension and preeclampsia, or preterm delivery.   Measuring a teen girl's blood for signs of prediabetes might help protect her against trouble in a later pregnancy, McCarthy's group said. https://www.usnews.com/news/health-news/articles/2024-09-24/prediabetes-in-teens-could-raise-odds-for-complicated-pregnancies-later XX Is there a link between IBD and type 1? In a recent and very large study, researchers looked at more than 630-thousdan people and found that irritable bowel disease seemed to significantly increase the risk of type 1 diabetes and vice versa. Interestingly, patients with IBD were found to have a significantly higher probability of formerly having contracted T1D, validating the bidirectional associations between these comorbidities. The highest risk was observed in patients with ulcerative colitis (aHR = 2.02), highlighting a stronger association with this IBD subtype. Additionally, over 70% of the study cohort was followed for more than ten years, reinforcing the robustness of these findings. https://www.news-medical.net/news/20240919/IBD-increases-type-1-diabetes-risk-revealing-a-bidirectional-link-between-the-two-conditions.aspx XX Roche plans to launch its first continuous glucose monitor (CGM) in Europe “in the coming weeks,” The Accu-Chek Smartguide has European approval for adults with Type 1 or Type 2 diabetes. Roche will roll out the CGM in the Netherlands, Switzerland and Germany. Accu-Chek Smartguide can be worn for 14 days, and features predictive algorithms that Roche hopes will differentiate it from competitors Abbott and Dexcom. However, it also must be calibrated at first using a finger stick, which the other brands don't require.   Roche developed the CGM with three different prediction tools: A feature to predict the risk of low blood glucose within 30 minutes, a feature to forecast glucose levels over the next two hours, and a feature to predict hypoglycemia risk at night.   Pau Herrero, an algorithm and decision support tech lead at Roche, said the device provides a different picture than the trend arrows other CGMs use, which typically forecast glucose levels over the next 20 minutes. The predictions are based on multiple days of patient data using machine learning models. The company is in “active discussions” with the Food and Drug Administration on bringing Accu-Chek Smartguide to the U.S., Moreiras said, adding that he “cannot commit to any timelines.” https://www.medtechdive.com/news/roche-cgm-launch-europe/726863/ XX Exciting news! iLet users can now invite friends and family to join their Bionic Circle to see their diabetes data and receive alerts. By accepting the invite and downloading our new Bionic Circle App, loved ones can monitor an iLet user's CGM values, meal announcements, insulin doses, and alerts from anywhere.   To learn how to invite followers and accept an invite, visit: https://lnkd.in/ghigJKMt XX Diabetes Canada has unveiled the key findings of a first-of-its-kind national survey on how widespread stigma, judgement and discrimination is for those who live with diabetes and the impact of those social experiences on the quality of life for people with diabetes. The survey shows that diabetes can not only negatively impact a person's physical health but can also negatively affect their personal relationships, work or studies, leisure activities, financial situation, and emotional well-being.   In fact, nearly 90% of people living with type 1 diabetes and 70% of people living with type 2 diabetes experience shame and blame for having diabetes.   “As someone who lives with type 2 diabetes, I know first-hand how stigma can negatively impact the quality of life for people living with this condition in Canada,” says Laura Syron, President & CEO of Diabetes Canada. “We need to change the conversation around diabetes—the values, beliefs and language—so that people living with this condition can feel more accepted and understood. These feelings can dramatically improve the likelihood that people living with diabetes can receive the support and care they need to better their health outcomes and their quality of life.” In the survey, key findings show how people living with diabetes must deal with unfair assumptions about what they can and cannot do, judgements if they consume specific foods, and being blamed for having diabetes. 40% of people with T1D never or rarely ask for support to help manage their diabetes when they need it.   56% of people with T2D never or rarely ask for support to help manage their diabetes when they need it.   https://finance.yahoo.com/news/diabetes-canada-releases-first-kind-101300695.html?guce_referrer=aHR0cHM6Ly93d3cuZ29vZ2xlLmNvbS8&guce_referrer_sig=AQAAAJIrWwjdye-ehrLNDt-LIGb5qTXaKDTIa8NWwiT7fKwFFgjDMN2nnINis6YfFePWP2ZA2DVYWXEIZQqRlQ4aKLFrYWgvw1jdI-t1n9kO6NIzdBCMXQNNCVl_S-75lDNip2SysHDJQmyqSc4wLjfDya3v9wwTWU-KgE_OqrPCTnlu XX Edgepark commercial XX This is National Glucose Awareness Week. Dexcom and Beyond Type 2 are teaming up for the new designation to encourage people to learn about the importance of glucose and its significant impact on overall health, especially for people with diabetes. The news release says: National Glucose Awareness Week will feature a variety of educational resources about the importance of glucose health and information about new, cutting-edge glucose biosensing technology. That technology is CGM.. now available over the counter as Dexcom's Stelo. Get moving: Participate in a nationwide step challenge (invitation code: glucose) from Sept. 30 to Oct. 13 to help improve your glucose health.† Step challenge participants can register to participate from Sept. 23-29, 2024 and will have the chance to compete for prizes. Get resources: Close the glucose knowledge gap with key educational resources from Beyond Type 2. https://www.businesswire.com/news/home/20240923896101/en/Dexcom-Beyond-Type-2-and-Retta-Establish-National-Glucose-Awareness-Week-to-Close-the-Glucose-Knowledge-Gap?utm_campaign=shareaholic&utm_medium=copy_link&utm_source=bookmark   XX Attention diabetes camp organizers! You're invited to apply for financial support for your need based scholarships. This is the Type 1 Diabetes Camps Project: 2025-2027 Campership Initiative The initiative will also provide limited funds for selected camps to expand their revenue development efforts, funds for professional development and funds for low-income camper recruitment efforts and indirect costs. The initiative is supported by $6 million in grant funding from The Leona M. and Harry B. Helmsley Charitable Trust and $900 thousand in funding from Eli Lilly and Company over the next three years. For more information about the RFP, please login and navigate to the publicly available RFPs: https://newventurefund.force.com/login XX Join us again soon!

On this episode of GoalChat, host Debra Eckerling discusses living Beyond Type A with KeishaMarie Douglas, Veteran Wingwomen Community; AJ Lauer, Thriving Ibis Leadership Solutions; and Evelyn Pacitti, Measurable Wellness. KeishaMarie, AJ, and Evelyn share their relationship with perfection, what caused them to embrace imperfection, and more. What is Perfectionism? - Evelyn: The vision of what in your head vs what's real .. and the non-stop loop of trying to match them - KeishaMarie: Doing the same thing and trying to get different results - AJ: Having an idea of how you want something to go Goals - AJ: Put something out into the world that is not 100% polished and perfect! - KeishaMarie: Stop holding yourself back - Evelyn: Put doing something imperfect/uncomfortable on your todo list Final Thoughts - KeishaMarie: Enjoy the journey. Laugh as much as possible - Evelyn: There's more flexibility in life than you give it credit for - AJ: Strive for progress over perfection Learn More About: KeishaMarie Douglas: KeishaMarieOnline.com AJ Lauer: ThrivingIbis.com Evelyn Pacitti: MeasurableWellness.com Debra Eckerling: TheDEBMethod.com/blog Learn more about your ad choices. Visit megaphone.fm/adchoices

Jaime Ferrer was diagnosed with type 1 at age three.. and this summer was drafted into Major League Baseball by the Minnesota Twins. I caught up with him to ask him your questions about works out, playing with a pump, how he managed the college recruitment process, and more. He's a great kid and this was a fun one. I should note that many of you know Jamie's mother Mila Ferrer. She's been blogging about her family's experience for a long time, does a lot of work with Beyond Type 1 and is an advocate for the Latino diabetes community. I've had the pleasure of working with her on some of the past Beyond Type 1 projects. Jaime was drafted by the Twins this summer and he's currently practicing and playing with their minor league team Fort Myers Mighty Mussels. He is also part of the Tandem Diabetes Ambassador program. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Follow Jaime Ferrer on Instagram Joint interview with Jaime and Mila Ferrer Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom  Edgepark Medical Supplies Check out VIVI Cap to protect your insulin from extreme temperatures Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.

In this episode, Lauren and Coach Neil chat about his preparation for his second full marathon with the Beyond Type 1 Team. They discuss listener questions about hydration, nutrition, blood sugar management, carbohydrate intake, preventing foot ulcers, and insulin pump settings during training and on race day. This episode gives you the pep talk and tips you need to accomplish your endurance running goals! Time Stamps:  (02:20) Neil's Marathon Background & Motivation(08:20) The Running Apps He Prefers(11:13) “The marathon is not the thing to be nervous about..it's a celebration party”(13:28) The Pride of Running with Type 1 Diabetes (16:55) Hydration & Water Stations(21:37) Fueling Strategies and Blood Sugar Management During Long Runs(37:06) The Importance of a Support System For Your Running Goals(40:03) Pump Placement While Running (41:39) “Do temporary mid run high blood sugars impact performance?”(45:35) Setting Goals, Celebrating Progress, and Expecting the Unexpected(54:37) Preventing Foot Ulcers While RunningWhat to do now:Follow me @lauren_bongiorno and @riselyhealth on Instagram to stay in the loop when new episodes drop.Learn more about our 1:1 coaching programs HERE.  Neil's Marathon Fundraiser HEREDisclaimer: Nothing you hear on the Reclaim your Rise podcast should be a substitute for personalized professional medical advice. Please always consult your physician or other medical professional before making any changes to your diet, insulin dosages, or healthcare plan. 

Alexi Melvin is making significant strides in the Broadway community as a producer in shows like "Here Lies Love," "The Outsiders," and "The Notebook". She highlights the struggle of balancing commercial success with artistic bravery, advocating for more support for innovative and risk-taking productions. Growing up with a professional baseball playing dad, she looks back on her journey to finding her calling, how she developed a love for the arts thanks to her mom, and the unwavering support she got from both parents along the way. With almost 100k followers on TikTok, she reflects on her experience with social media, transitioning from queer relatable content to theater-focused posts, and how her audience has positively received this shift. She also delves into the role of social media in modern theater marketing, and how shows like "The Outsiders" leverage platforms like TikTok to reach more audiences. As more and more shows feature queer stories and diverse casting like "The Notebook" and "Illinois", she stresses the need for more queer representation on stage and the challenges of achieving this in an industry dominated by big-budget musicals. Alexi opens up about her journey with pronouns and gender identity, sharing her transition from they/them to she/they and the importance of creating a safe environment for self-exploration. Whether it's producing or posting on social media, she encourages aspirants to channel their “fan girl energy” and not shy away from doing what you're a fan of. Alexi Melvin is a multi-Tony Award-nominated Broadway producer for her work on “Illinois” and “The Outsiders”. She has also done work on the producing teams of “Here Lies Love” and “The Notebook”. A writer and actor who takes the term multi-hyphenate to an all-new level, she is a proud member of and advocate for the LGBTQ-plus community and is deeply involved with type one diabetes organizations such as JDRF and Beyond Type 1. She has notable voice work in “Rogue One: A Star Wars Story” and “Star Wars: The Last Jedi”, onscreen appearances in “Time Out of Mind”, and “Quarter”, and a significant presence as an LGBTQ-plus creator on TikTok with almost 100,000 followers. Connect with Alexi: TikTok: @theonlylex Instagram: @thealexijames Connect with The Theatre Podcast: Support the podcast on Patreon: Patreon.com/TheTheatrePodcast YouTube: YouTube.com/TheTheatrePodcast Threads, Twitter & Instagram: @theatre_podcast TikTok: @thetheatrepodcast Facebook.com/OfficialTheatrePodcast TheTheatrePodcast.com My personal Instagram: @alanseales Learn more about your ad choices. Visit megaphone.fm/adchoices

In this episode, Lisa and Kristina discuss:Strategies for striking the balance between parental involvement and teen independence.How to listen to and validate your teen's aspirations before giving advice. Why parents need to have honest discussions about their college budget and their financial realities. The importance of highlighting your student's voice and ownership during the application process.Key Takeaways: You do not want to project your experiences, achievements, or failures on your student. They need to live their independent life, not your life vicariously. If you believe your teen is wrong, you can still validate and empathize with them before redirecting them to more constructive thoughts and behavior.It's possible to help your students see the throughlines of their desires by asking why, without telling them your thoughts.There are ways for you to talk to your student about college budget and finances without them knowing every detail of how much you make.While the journey is the student's it's still possible for the parent to play an important, supportive role.  “Support has to be authentic and genuine from the parent, meaning if you're going to support your child in terms of their life, their outcomes, all those things, they have to feel that it's true.” – Kristina DooleyAbout Kristina Dooley: Kristina L. Dooley is a Certified Educational Planner (CEP) and founder of Estrela Consulting, an Ohio-based independent educational consulting firm. Kristina has more than 20 years of experience working with students from around the world, navigating the complex college and school search processes. A first-generation college student, she graduated from Hiram College (B.A.) and Kent State University (M.A.). In addition to her work with students, Kristina is an instructor for the University of California Irvine teaching College Consulting Resources, and also serves as a faculty member of the IECA Summer Training Institute for aspiring educational consultants. Kristina is the Past President of the Independent Educational Consultants Association (IECA), and holds membership in AICEP, NACAC, and the Ohio and International Associations for College Admission Counseling (OACAC & IACAC).  In her free time, Kristina volunteers for Beyond Type 1 and JDRF, and serves as a mentor for College Now Greater Cleveland. She resides in Northeast Ohio with her husband and their 13-year-old triplets. Episode References:Free Video: How to guide your teen to choose the right major, college, & career flourishcoachingco.com/course #048 Building Motivation & Stress Tolerance for Happy Teens with Ned Johnson  #062 Gap Year: Is it a better freshmen start?  #013 The Many Advantages of a Gap Year with Holly Bull Get Lisa's Free on-demand video: How-to guide for your teen to choose the right major, college, & career...(without painting themselves into a corner, missing crucial deadlines, or risking choices you both regret). flourishcoachingco.com/videoConnect with Kristina:Instagram: instagram.com/estrela_consulting Facebook: facebook.com/EstrelaConsulting LinkedIn: linkedin.com/in/kristinadooley Website: estrelaconsulting.com Connect with Lisa:Website: https://www.flourishcoachingco.com/YouTube: https://www.youtube.com/@flourishcoachingcoInstagram: https://www.instagram.com/flourishcoachingco/LinkedIn: https://www.linkedin.com/company/flourish-coaching-co

This episode of Flow Radio features Nate Checketts, CEO and co-founder of the premium men's activewear company, Rhone. A lifelong entrepreneur who founded four companies before turning 30, Checketts spoke with the Flow Research Collective about what it takes to show up and follow through for your family, your community, and your wildest professional goals. The crew also discusses how to create opportunities for flow to fulfill a full slate of ambitions. In This Episode: 0:00 Introduction 04:41 Community Building and Resilience 07:37 Creating a Resilient Work Culture 16:45 Creating Opportunities for Flow 21:39 Teaching Resilience to Children 33:06 Advice for Leaders 35:59 Resilience and Flow About The Guest: Nate Checketts is the Co-Founder & CEO of Rhone, a performance lifestyle brand founded in 2014. Prior to Rhone, Nate worked for and consulted with some of the biggest technology and entertainment properties in the world including Cisco, The National Football League, Legends, FanVision and Sport Radar. Nate is also an avid entrepreneur who founded and launched 4 companies before the age of 30, including Rhone and Mangia Technologies, whose patents were later acquired by the San Francisco 49ers. In 2020 Nate was selected by the Sports Business Journal to their 2020 list of Forty leaders under Forty. In addition to Rhone, Nate also serves as Chairman of the Board to Beyond Type 1, a non-profit dedicated to the community of those with Type 1 Diabetes. Nate graduated from Brigham Young University with a BA in Finance. He and his wife Dayna reside in Connecticut with their three young boys, Gabriel, William and Nicholas. Episode Resources: Website: https://www.rhone.com/ LinkedIn: https://www.linkedin.com/in/natechecketts Instagram: https://www.instagram.com/natechecketts Facebook: https://www.facebook.com/nate.checketts Flow Radio Is Presented By Flow Research Collective Are you an entrepreneur, a leader, or a knowledge worker, who wants to harness the power of flow so you can get more done in less time with greater ease and accomplish your boldest professional goals faster? If the answer is yes, then our peak-performance training Zero To Dangerous may be a good fit for you. Flow Research Collective is a leading neuroscience research and training company. If you're interested in learning the science-backed techniques we used to train top executives at Facebook, Audi and even the Navy SEALs, click the link here: ⁠https://www.flowresearchcollective.com/zero-to-dangerous/overview⁠ Follow Flow Research Collective: YouTube: ⁠https://www.youtube.com/@flowresearchcollective⁠ Instagram: ⁠https://www.instagram.com/flowresearchcollective⁠ LinkedIn: ⁠https://www.linkedin.com/company/flowresearchcollective⁠ X: ⁠https://twitter.com/thefrc_official⁠ Facebook: ⁠https://www.facebook.com/flowresearchcollective⁠ Spotify: ⁠https://open.spotify.com/show/6RQY0d5rdlEiinHEtfWy6A⁠ Website: ⁠https://www.flowresearchcollective.com⁠ Flow Research Collective was founded by Steven Kotler, one of the world's leading experts on human peak performance. He is an award-winning journalist and author with over ten bestselling books.

It's In the News! A look at the top diabetes stories and headlines happening now. Top stories this week: The annual ATTD conference wraps up with news about CGMs, including new FDA approvals and a look at CGMs outside of the US, new eyedrops are being studied to treat diabetic eye disease and Beyond Type 1 opens applications for their annual Beyond Scholars. Transcript and links below Find out more about Moms' Night Out  Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom  Edgepark Medical Supplies Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens  Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com  

Las Vegas Raiders own DeAndre Carter has overcome adversity in all ways possible. After going undrafted in the NFL, he found a way to win and has turned it into a 8 year career. DeAndre discusses it wasn't always easy, especially playing with Type 1 Diabetes... yes DeAndre also is part of the Beyond Type 1 organization and his experience playing football from youth to high school to college to the NFL all while having Diabetes is very inspiring. Lastly the fellas discuss grit, and the elite mindset it takes to chase greatness.

An Interview with my daughter Lauren Rotach _______________________________________ The Happy Diabetic Website https://www.happydiabetic.com Facebook https://www.facebook.com/ChefRobertLewisTheHappyDiabetic Instagram https://www.instagram.com/happydiabetic   Taking Control of Your Diabeties www.tcoyd.org Beyond Type 2 www.beyondtype2.org   Recipe of the Podcast Lauren's Slow Cooker Pork Carnitas Lauren's Slow Cooker Pork Carnitas is an amazingly easy and delicious recipe that is full of flavor and cooks all day to tender and juicy perfection! This is bound to be a savory favorite that you will make again and again! Ingredients 4 pounds pork shoulder roast 1 tablespoon chili powder 1 teaspoon cumin 1 teaspoon oregano 1 teaspoon salt 1 teaspoon pepper 3/4 cup orange juice 1/4 cup lime juice 4 cloves garlic minced 1 onion quartered  Instructions In a small bowl combine chili powder, cumin, oregano, salt, and pepper. Rub on the outside of the pork shoulder rub thoroughly. In the slow cooker, combine orange juice, lime juice, garlic and onion. Place pork on the top. Cook on low for 8 hours or high 4-5 hours. Remove roast from slow cooker and shred. Return to slow cooker and heat for an additional 30 minutes. Remove the pork from the slow cooker and place on a baking sheet. Broil in the oven for 3-4 minutes to brown the edges of the pork. Nutrition Calories: 153kcal | Carbohydrates: 4g | Protein: 18g | Fat: 7g | Saturated Fat: 2g | Sodium: 276mg | Sugar: 2g    

Beyond Type 1 has made it clear that it's no longer on the side of people living with type 1 diabetes. Support Beta Cell on Patreon. More on Beyond Type 1 (in chronological order): Sierra Sandison's resignation from the Beyond Type 1 Leadership Council Craig's letter of resignation from Beyond Type 1 Leadership Council Craig and Hannah discuss Beyond Type 1 accepting money from insulin makers Beyond Type 1's attempt to stop affordable insulin in Maine

Sam Talbot's fall from grace opened up a Pandora's box of hidden payments by pharma to Beyond Type 1. Support Beta Cell on Patreon. . More on Beyond Type 1 (in chronological order): Sierra Sandison's resignation from the Beyond Type 1 Leadership Council Craig's letter of resignation from Beyond Type 1 Leadership Council Craig and Hannah discuss Beyond Type 1 accepting money from insulin makers Beyond Type 1's attempt to stop affordable insulin in Maine

It's In the News, a look at the top stories and headlines from the diabetes community happening now. Top stories this week: infusion set recall, update on ViaCyte stem cell research, a few new studies look at sleep and diabetes, actual clinical research into cinnamon for type 1 and lots more. Links & transcript below Find out more about Moms' Night Out  Please visit our Sponsors & Partners - they help make the show possible! Take Control with Afrezza  Omnipod - Simplify Life Learn about Dexcom  Edgepark Medical Supplies Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens  Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com Episode transcript: Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX In the news is brought to you by Edgepark simplify your diabetes journey with Edgepark XX Our top story this week… XX A recall of infusion sets. This is the VariSoft infusion set used with Tandem Diabetes Pumps. The recall here isn't new.. but the FDA has changed the rating to Class 1, its most serious. The VariSoft version is flexible and can be put in place at an insertion angle anywhere between 20 and 45 degrees, it's usually recommended for people “who are thin or who have scar tissue or limiting potential insertion sites.” The problem is that the connector can detach from the set – which means no insulin is going in. To date, according to the FDA notice, there has only been one report of injury related to the recall. https://www.fiercebiotech.com/medtech/fda-gives-class-i-recall-rating-infusion-sets-used-tandem-insulin-pumps XX An already existing drug may help preserve beta cell function in people with new onset type 1. It's got a very long name, so it's usually referred to as DFMO.  It inhibits a pathway, which plays a role in the inflammatory responses in autoimmune diseases, including type 1 diabetes. It's sold under a few names for different conditions, including Vaniqa which is a cream for unwanted hair growth in women. It also has orphan designations for treating various cancers, including neuroblastoma. The new safety study by Sims and colleagues, which was published November 1 in Cell Medicine Reports, enrolled 41 people with type 1 diabetes that had been diagnosed within the previous 8 months, including 31 children. Participants were randomly assigned to undergo oral treatment with DFMO at one of five doses or placebo for 3 months, with 3 additional months of follow-up. Following a mixed-meal tolerance test at 6 months, the C-peptide area under the curve ― a measure of beta-cell function ― was significantly higher with the three highest DFMO doses compared to placebo (P = .02, .03, and .02 for 125 mg/m2, 750 mg/m2, and 1000 mg/m2, respectively). https://www.medscape.com/viewarticle/998671?form=fpf XX Despite earlier promising findings, it seems unlikely that cinnamon can improve blood sugar levels in people with type 1, or insulin-dependent, diabetes, researchers report. Previous research has shown that cinnamon appears to help fat cells recognize and respond to insulin. In test tube experiments and in animal studies, the spice led to a noteworthy increase in the processing of glucose. Moreover, in a previous study of people with type 2, or non-insulin dependent, diabetes, those who incorporated a small amount of cinnamon each day for 40 days into their normal diets experienced a healthy drop in blood sugar levels. But a new study of teenagers with type 1 showed cinnamon made no difference after 90 days . In fact, "In essentially all outcomes...the trend favored the placebo group, although did not achieve statistical significance," the researchers report.   https://www.reuters.com/article/us-cinnamon-diabetes-idUSSIB65463020070406/ XX New results from ViaCyte clinical trials – that's a stem cell-based treatment for type 1 diabetes.  The therapy aims to replace the insulin-producing beta cells that people with type 1 diabetes lack. Dubbed VC-02, the small medical implant contains millions of lab-grown pancreatic islet cells, including beta cells. The devices—approximately the size of a Band-Aid and no thicker than a credit card—are implanted just beneath a patient's skin where it is hoped they will provide a steady, long-term regulated supply of self-sustaining insulin. The clinical trial was conducted at Vancouver General Hospital, with additional sites in Belgium and the U.S. Ten participants, each of whom had no detectable insulin production at the start of the study, underwent surgery to receive up to 10 device implants each.   Six months later, three participants showed significant markers of insulin production and maintained those levels throughout the remainder of the year-long study. These participants spent more time in an optimal blood glucose range and reduced their intake of externally administered insulin.   One participant, in particular, showed remarkable improvement, with time spent in the target blood glucose range increasing from 55% to 85%, and a 44% reduction in their daily insulin administration.   In another ongoing trial, the UBC-VCH team is investigating whether a version of the device containing cells that have been genetically engineered to evade the immune system, using CRISPR gene-editing technology, could eliminate the need for participants to take immunosuppressant drugs alongside the treatment. https://medicalxpress.com/news/2023-11-stem-cell-based-treatment-blood-sugar.html XX A new look at sleep quality in people with type 1 finding that more time in range means better sleep. No surprise here, but important to quantify. Interestingly, recurrent high or low blood sugar, rather than constant or prolonged higher levels seems associated with worse sleep. A study in adults with type 1 diabetes showed that 17.7% wake up every night, and 53.5% wake up once or twice a week1. This was a small pilot study – the researchers want to now move to a larger one. https://www.nature.com/articles/s41598-023-47351-x XX New study looks at women, sleep and insulin sensitivity. This is a small study, only 40 women, which found that particularly post menopausal women who sleep less 7 hours per night may have impaired insulin sensitivity regardless of body fat. Nearly 40 women were randomly assigned to either restricted sleep or adequate sleep for 6 weeks, then crossed over to the other sleep condition. During sleep restriction, women slept an average of 6.2 hours per night vs 7-9 hours per night. Both fasting insulin levels and insulin resistance were significantly increased during sleep restriction with more insulin needed to normalize glucose. These researchers say if sustained over time, it is possible that prolonged insufficient sleep among individuals with prediabetes could accelerate the progression to type 2 diabetes https://www.medscape.com/viewarticle/insufficient-sleep-impairs-womens-insulin-sensitivity-2023a1000tlz XX XX Pregnant women with type 2 who use CGM saw improvement in blood glucose levels but only if they used the device more than 50% of the time during their pregnancy. This study involved high-risk women from regional and remote Australia all with type 2. No changes in diabetes metrics were seen in those who used the CGM only early or late in their pregnancies. https://www.healio.com/news/endocrinology/20231128/greater-use-of-cgm-linked-to-glycemic-benefits-for-pregnant-women-with-type-2-diabetes XX Commercial XX When it comes to walking and type 2 diabetes risk, it's not just how much you do it that helps — it's also how fast you move, a new study has found.   Brisk walking is associated with a nearly 40% lower risk of developing type 2 diabetes later in life, according to the study published Tuesday in the British Journal of Sports Medicine.   “Previous studies have indicated that frequent walking was associated with a lower risk of developing type 2 diabetes in the general population, in a way that those with more time spent walking per day were at a lower risk,” said the study's lead author Dr. Ahmad Jayedi, a research assistant at the Social Determinants of Health Research Center at the Semnan University of Medical Sciences in Iran. The study authors reviewed 10 previous studies conducted between 1999 and 2022, which assessed links between walking speed — measured by objective timed tests or subjective reports from participants — and the development of type 2 diabetes among adults from the United States, the United Kingdom and Japan.   After a follow-up period of eight years on average, compared with easy or casual walking those who walked an average or normal pace had a 15% lower risk of developing type 2 diabetes, the researchers found. Walking at a “fairly brisk” pace meant a 24% lower risk than those who easily or casually walked. And “brisk/striding walking had the biggest benefit: a 39% reduction in risk. Easy or casual walking was defined as less than 2 miles per hour. Average or normal pace was defined as 2 to 3 miles per hour. A “fairly brisk” pace was 3 to 4 miles per hour. And “brisk/striding walking” was more than 4 per hour. Each kilometer increase in walking speed above brisk was associated with a 9% lower risk of developing the disease. https://www.cnn.com/2023/11/28/health/walking-speed-lowers-diabetes-risk-wellness/index.html XX Not a lot of events happening in December but there are two to tell you about: Beyond Type 2 virtual summit https://beyondtype2.org/registration-type-2-diabetes-virtual-summit/

Nate Checketts is the Co-Founder & CEO of Rhone, a premium men's performance lifestyle company. In addition to Rhone, Nate also serves as Chairman of the Board of Beyond Type 1, a non-profit dedicated to the community of those with Type 1 Diabetes. In this episode, Nate and I discuss why searching for balance in life is a losing game and why we should be seeking harmony to align all areas of our lives. We also dive into why Nate left his job at the NFL to build a brand that matters, how to build resilience through tough times, and how faith has transformed him into the leader he is today. Key Points: What Nate learned from almost losing his son Doubt your doubts before you doubt your faith How Rhone was able to thrive through the pandemic Finding ways to stand out in a competitive market What separates successful people from everyone else Why Nate left his job at the NFL Building a brand that matters The profound meaning behind Rhone's iconic logo Investing in men's mental health Empowering the next generation of male leaders Why we should stop searching for balance in our lives Pursue harmony to find more fulfillment in life Nate's definition of Pure Ambition Connect with and follow Nate: Instagram LinkedIn Shop Rhone Connect with me: Download my FREE training app here: Upspace App Instagram: @dominicfusco TikTok: @dom_fusco YouTube: Dominic Fusco LinkedIn: Dominic Fusco Resources: Elevate your hydration and hit your protein goals with no sugar and nothing artificial and get 20% off with code DFUSCO20 at https://pwrlift.com/discount/DFUSCO20 Look, feel, and perform your best in life by leveling up your wardrobe with Rhone and receive 20% your order https://www.rhone.com/?discount=DOMINICFUSCO20&utm_campaign=dominicfusco&utm_source=GRIN&utm_medium=instagram&platform=grin&link_id=921134&token=cRNgnNE1woLm4mqYsibeLOXcOd8GYP6V&contact_id=6f29d8c5-f52e-46a8-a099-e7f8abb90c89&attribution_window=30 Want to help the show grow? Sweet! Here's what you can do: Share this episode with someone who would find value in it. Leave a 5-star rating and review on the podcast app and let me know your honest opinion! Share this episode on your IG story and tag me @dominicfusco

Join Ken Pilot as he speaks with Co-Founder and CEO of Rhone, Nate Checketts, about his menswear business focused on fitness, comfort and everyday wear.Prior to Rhone, Nate worked for and consulted with some of the biggesttechnology and entertainment properties in the world including Cisco, The NationalFootball League, Legends, FanVision and Sport Radar. Nate is also an avid entrepreneur who founded and launched 4companies before the age of 30, including Rhone and Mangia Technologies, whose patents were later acquired by the San Francisco 49ers. In 2020 Nate was selected by the Sports Business Journal to their 2020 list of Forty leaders under Forty.In addition to Rhone, Nate also serves as Chairman of the Board to Beyond Type 1, a non-profit dedicated to the community of those with Type 1 Diabetes. Nate graduated from Brigham Young University with a BA in Finance. He and his wife Dayna reside in Connecticut with their three young boys, Gabriel, William and Nicholas.About Rhone was founded in 2014 by brothers Nate & Ben Checketts. Rhone is a premium men's wellness brand that creates best in class performance-driven apparel that is engineered for an active lifestyle. Rhone is dedicated to using their platform and products to address and discuss the complex issues that modern men face. From raising awareness around the mental health crisis, to building mutually supportive communities, to providing men with practical tools and resources to navigate relationships, Rhone seeks to support men while providing them with versatileclothing for every aspect of their daily routine. Currently, Rhone has more than ten retail stores across the U.S., all of which are used for building community through various initiatives such as the brand's signature Mind & Muscleevents. Rhone is also sold in all Equinox locations, and available nationwide at Nordstrom, Bloomingdale's, Dillard's, SCHEELS, select CorePower Yoga locations, and more than 350 gyms and specialty stores across the country. Rhone is also a proud partner of Stitch Fix. More information can be found at www.Rhone.com.Key Highlights Include:Rhone's Origin and Vision: Rhone, a men's performance lifestyle brand, was founded with a vision to fill a void in the men's fashion space. The founders, including Nate Checketts and his brother Ben, aimed to create a brand that offered high-quality, versatile, and high-performance clothing that could be worn in various settings, blurring the lines between work and leisure attire.Balancing Family and Business: Nate and his brother Ben, along with their brother-in-law, founded Rhone as a family venture. They emphasize that working together as a family has been a positive experience, and Ben's interest in clothing design complemented Nate's entrepreneurial background.Omni-Channel Approach: While Rhone began as an e-commerce brand, it recognized the importance of an omni-channel approach. They expanded into physical retail stores, selecting high-end partners like Equinox to offer their products. This strategic move allowed them to meet customers where they were and helped them gain recognition in the market.Retail Expansion and Profitability: Rhone currently operates 15 retail stores, and they prioritize profitability over rapid expansion. They are careful in selecting wholesale partners, ensuring that the brand is represented appropriately. All of their stores are profitable, which has provided a strong foundation for future growth.Future Growth and Product Expansion: Rhone is exploring opportunities for growth, including potential expansion into the international market. They are also considering product line extensions, including potentially re-entering the women's market. However, their primary focus remains on delivering exceptional quality products and ensuring the customer's experience is at the forefront of their decisions.Investor Criteria: The company looks for investors who can bring value in three key areas:Reputation: They prefer investors with a notable name that they can leverage for credibility.Network: Investors who can make valuable introductions to other influential individuals.Expertise: Those who can offer valuable insights and advice when needed.Navigating Challenges During COVID: The COVID-19 pandemic brought both business and personal challenges. Managing the business crisis while also dealing with the human crisis was particularly difficult. It led to burnout and a realization that changes were needed.Growth and Transformation: Bringing in experienced executives who have successfully navigated company growth from smaller to larger stages was transformative for the business. This allowed the CEO to focus on their strengths and enabled the company to scale effectively.Focus on Mental Health: The brand's commitment to mental health has been a core part of its mission from the start. They recognize the unique challenges that men face in seeking and receiving mental health support. They've integrated physical activity with group therapy sessions to create a supportive community.Innovation and Technology: The company embraces technology as an enabler and is particularly interested in advancements related to customer data, retail analytics, and AI-driven customer service enhancements. They're using technology to gain a comprehensive view of their customers and to optimize their operations.

It's In the News, a look at the top stories and headlines from the diabetes community happening now. Top stories this week: Abbott acquires Bigfoot, a new study looks at low-dose aspirin to prevent type 2, researchers look into whether the AI ChatGPT can answer FAQs about diabetes, Beyond Type Run is back for the NYC Marathon, and more! Our previous episode with Bigfoot Biomedical: https://diabetes-connections.com/?s=bigfoot Join us for Moms' Night Out! (use promo code School30 to save) Please visit our Sponsors & Partners - they help make the show possible! Take Control with Afrezza  Omnipod - Simplify Life Learn about Dexcom  Learn about Edgepark Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens  Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and these are the top diabetes stories and headlines happening now XX In the news is brought to you by Edgepark simplify your diabetes journey with Edgepark XX Our top story this week – Abbott scoops up Bigfoot Biomedical. The deal is expected to close later this year – no financial terms yet disclosed. Abbott and Bigfoot have worked together since 2017 on a connected insulin pen system. Bigfoot Unity exclusively works with Abbott's FreeStyle Libre® Long time listeners will recall that Bigfoot was founded in 2015 around serving people with type 1 diabetes with a closed loop pump system that Byran Mazlish had developed for his wife and son. Mazlish was very secretive at first about the algorithm – this was before people were sure the FDA wouldn't crack down on them – so a journalist nicknamed him Bigfoot. Along the way, the company pivoted to CGM connected SmartPens. I believe Bigfoot was my third interview, back in 2015 – I'll ink up all of the interviews I've done with them in the show notes. https://diabetes-connections.com/?s=bigfoot https://www.prnewswire.com/news-releases/abbott-to-acquire-bigfoot-biomedical-furthering-efforts-to-develop-personalized-connected-solutions-for-people-with-diabetes-301918254.html XX Low-dose aspirin reduces the risk for type 2 diabetes among older adults and slows the increase in fasting glucose levels over time, new research finds. The data come from a secondary analysis of ASPREE, a double-blind, placebo-controlled trial of healthy adults aged 65 years or older, showing that 100 mg of aspirin taken daily for about 5 years did not provide a cardiovascular benefit but did significantly raise the risk for bleeding. It's a big study, more than 16-thousand people. This new analysis shows that individuals taking aspirin had a 15% lower risk for developing type 2 diabetes and that the medication slowed the rate of increase in fasting plasma glucose, compared with placebo, during follow-up. However, lead author Sophia Zoungas, MBBS, PhD, head of the School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia, says, "Major prescribing guidelines now recommend older adults take daily aspirin only when there is a medical reason to do so, such as after a heart attack… Although these new findings are of interest, they do not change the clinical advice about aspirin use in older people at this time." https://www.medscape.com/viewarticle/996058 XX A class-action lawsuit filed against Medtronic (NYSE: MDT)+ alleges that the company's insulin delivery devices shared patient data with third parties. The lawsuit — filed by the plaintiff “A.H.” in U.S. District Court in Central California — levels allegations against Medtronic and its MiniMed and InPen devices. It addresses MiniMed's transmission and disclosure of personally identifiable information and protected health information to Google and other third parties. Per the lawsuit, the data was transmitted via tracking and authentication technology, including Google Analytics, Crashlytics, Firebase Authentication and related tools. A.H. says these technologies, installed on the website and/or mobile applications, include the InPen iOS and Android applications. “Information about a person's health is among the most confidential and sensitive information in society, and its mishandling can have serious consequences, including embarrassment, discrimination, and denial of insurance coverage,” the lawsuit reads. A Medtronic spokesperson issued the following statement via email: We have strong processes, technologies, and people in place to safeguard and protect our information and systems, the information of our business partners, and most importantly, the privacy and safety of the patients and healthcare providers that use our products.” https://www.massdevice.com/lawsuit-patient-data-sharing-medtronic-diabetes/ XX Interesting new way to look at type 2 – not weight loss or medication, but about reducing how much blood glucose goes up and stays up after eating and drinking. University of Virginia Daniel Cox says this is called Glucose Everyday Matters, or GEM – aims to prevent blood sugar spikes via educated food and drink selection. This is coupled with physical activity to hasten recovery when blood-sugar spikes do occur. So someone might indulge in a piece of fruit or a small, sweet treat, knowing how it will affect them, and then go for an evening stroll to help even out their blood sugar. Sounds really simple, but in its first study, it helps almost 70-percent of people put their type 2 into remission without weight loss or medication. The National Institutes of Health has provided $3.5 million for a large-scale clinical trial Cox himself went from an A1C of 10.3 at the time of diagnoses to reading consistently under 6.0 for the past 13 years on no medication using his approach. https://newsroom.uvahealth.com/2023/08/31/radical-new-approach-to-managing-type-2-diabetes-receives-3-5-million/ XX Final preparations are in place to initiate the first clinical site for DIAGNODE-3 in the United States, and additional sites are expected to be initiated over the coming months. Approximately 10-12 clinical sites across the US are planned to be initiated, expanding the DIAGNODE-3 trial in the US and eight European countries to approximately 60 clincal sites in total. DIAGNODE-3 is designed to confirm the efficacy and safety of the antigen-specific immunotherapy Diamyd® in patients aged 12 to 29 years recently diagnosed with type 1 diabetes and carrying the genetic HLA DR3-DQ2 marker. Approximately 40% of all screened patients carry the genetic HLA DR3-DQ2 haplotype. This proportion aligns well with expectations based on previous Diamyd® clinical trials and published epidemiological research. Supported by published retrospective analyses and prospective clinical trials, the presence of the genetic HLA DR3-DQ2 haplotype determines the likelihood of responding to Diamyd® therapy, and serves as one of the main inclusion criteria in the DIAGNODE-3 trial. "Patient recruitment is a complex and central element in any trial and it is encouraging to see a significant and continuous uptick in the screening rate and that the observed frequency of the genetically defined responder group enrolled into DIAGNODE-3 confirms our previous observations", says Ulf Hannelius, President & CEO of Diamyd Medical. "This shows the operational and clinical feasibility of our precision medicine approach to Type 1 Diabetes and we look forward to expanding the trial to the United States". https://finance.yahoo.com/news/registrational-phase-iii-trial-type-142600082.html XX A low-carbohydrate diet during pregnancy may have some benefits in gestational diabetes, but overall, low-carbohydrate diets are not associated with any significant differences in outcomes. That was the conclusion of a presentation at the ADA Scientific Sessions. That was back in June but I just learned about it, so I'm passing along to you in case you missed it as well. During a debate at the American Diabetes Association Scientific Sessions, Amy M. Valent, DO, MCR, associate professor in the division of maternal-fetal medicine in the department of obstetrics and gynecology at Oregon Health & Science University, said identifying Teri L. Hernandez, PhD, RN, associate dean of research and scholarship in the College of Nursing and professor in the department of medicine and the division of endocrinology, metabolism and diabetes at the University of Colorado Anschutz Medical Campus, agreed that the first line of therapy with gestational diabetes is nutrition. However, Hernandez said, low-carbohydrate diets are not the only approach in gestational diabetes treatment with nutrition. Currently, dietary advice for treating gestational diabetes is inconsistent, and current professional guidelines have limitations and biases, according to Valent. Different diet strategies include low-carbohydrate, low glycemic index and total energy restriction eating plans, according to Valent. Valent said ACOG guidelines recommended a low-carbohydrate diet for gestational diabetes until the most recently revised edition in January. Valent reviewed several major landmark studies demonstrating that gestational diabetes treatment can decrease pregnancy complications such as preeclampsia and large for gestational age infants. “These studies were in the era where treatment of diabetes in pregnancy involved recommending a low-carbohydrate diet,” Valent said. “The concern with lowering carbohydrates is the risk of consuming lower nutrient-dense foods and resulting in the body to produce ketones, which may be associated with negative effects on the developing baby.” “Pregnancy is dynamic. Nobody's the same today as they were yesterday. They're going to be different 1, 2 or 3 weeks from now, and the nutritional demands and the fetal growth and development stage are going to be different,” Valent said. “So, nutritional demands are going to vary.” Hernandez also added that women and girls tend to be priced out of good nutritional patterns, which is an issue not only in the pregnancy field, but also in the global community. According to Hernandez, it is important to create ways moving forward to identify what nutritional patterns are best that are also affordable for families, especially in lower-income settings. https://www.healio.com/news/womens-health-ob-gyn/20230905/experts-debate-benefits-of-lowcarb-diets-for-gestational-diabetes XX XX Commercial – Edgepark XX Can ChatGPT help answer questions about diabetes? In a recent study published in the journal PLoS ONE, researchers tested chatGPT, a language model geared for discussion, to investigate whether it could answer frequently asked diabetes questions. In the present study, researchers evaluated ChatGPT's expertise in diabetes, especially the capacity to answer commonly requested questions related to diabetes in a similar manner as humans. The 'Frequently Asked Questions' section of the Diabetes Association of Denmark's website, viewed on 10 January 2023, included eight questions. The researchers designed the remaining questions to correlate to particular lines on the 'Knowledge Center for Diabetes website and a report on physical activity and diabetes mellitus type 1. Across the 10 questions, the proportion of correct responses ranged from 38% to 74%. Participants correctly identified ChatGPT-generated replies 60% of the time, which was over the non-inferiority threshold. Males and females had 64% and 58% chances of accurately recognizing the artificial intelligence-generated response, respectively. Individuals who had past contact with diabetes patients had a 61% chance of precisely answering the questions, compared to 57% for those who had no prior contact with diabetes patients. In contrast to the initial premise, participants could discern between ChatGPT-generated and human-written replies better than tossing a fair coin. While ChatGPT demonstrated some potential for accurately answering frequently asked questions, issues around misinformation and the lack of nuanced, personalized advice were evident. As large language models increasingly intersect with healthcare, rigorous studies are essential to evaluate their safety, efficacy, and ethical considerations in patient care, emphasizing the need for robust regulatory frameworks and continuous oversight. https://www.news-medical.net/news/20230905/Can-ChatGPT-be-a-diabetes-consultant-Study-probes-the-potential-and-pitfalls.aspx XX SAN MATEO, Calif., Aug. 24, 2023 /PRNewswire/ -- On November 5, diabetes nonprofit Beyond Type 1 will join more than 550 official charity partners and philanthropists raising awareness and funds while participating in the world's largest marathon, the TCS New York City Marathon. This year, the organization is expanding its 50-person team, Beyond Type Run, to include people living with type 1 or type 2 diabetes, as well as caregivers to those living with diabetes. "Since 2017, we've featured more than 200 runners on our teams who've exemplified what it means to survive and thrive with diabetes," said Beyond Type 1 CEO Deborah Dugan. Beyond Type 1 announces the 2023 NYC Marathon team to raise awareness and funds for people living with diabetes As a part of the Beyond Type Run team, runners will be advocating to raise awareness and funds for Beyond Type 1's portfolio of educational resources, awareness campaigns and peer-to-peer support programs for people impacted by diabetes. This advocacy is elevated through the NYRR Official Charity Partner Program, which offers opportunities for nonprofit organizations to raise funds to support their missions and services. Dexcom and Tandem Diabetes Care are presenting sponsors of Beyond Type Run for a fourth consecutive year. The TCS New York City Marathon Official Charity Partner Program has raised more than $440 million for more than 1,000 nonprofit organizations since its establishment in 2006. https://www.prnewswire.com/news-releases/team-of-50-individuals-impacted-by-diabetes-prepare-for-the-2023-tcs-new-york-city-marathon-301909163.html XX MNO update On the podcast next week.. tandem diabetes celebrity panel from friends for life – Hollywood, the NFL and NASCAR. Last week's episode was Benny off to college That's In the News for this week.. if you like it, please share it! Thanks for joining me! See you back here soon. ----  

Ginger (Type 1) was last on the podcast in February and, at that time, we primarily discussed her usage of Metformin. When her February episode came out, she was using both Metformin and Ozempic (newly started) to control her dawn phenomenon and improve insulin sensitivity. She continues to use both drugs and has developed a good understanding of how they work in her body. I thought it would make sense to have her back on to get an update on how things are going for her as she now has 9 months of Ozempic under her belt. Even if you are not a Type 1, I think you find this episode to be extremely informative. We discuss in depth such topics as other similar drugs to Ozempic (Wegovy, Trulicity, Mounjaro), weight loss, hunger while on these drugs, and insulin needs over time, etc.In addition to discussing Ozempic, we talk about low blood sugars (how to avoid over treating them) and her new book on exercise and Type 1 Diabetes (see link below).Enjoy!*Prior podcast episodes with Ginger:https://stream.redcircle.com/episodes/cc0458ae-8364-4e3e-a3a0-46c4506eacf1/stream.mp3https://stream.redcircle.com/episodes/cc0458ae-8364-4e3e-a3a0-46c4506eacf1/stream.mp3*Check out her website for links to her books and the articles she has written.https://www.gingervieira.com*Find her on Twitter at @GingerVieira*Ginger's new book: Exercise with Type 1 Diabeteshttps://www.amazon.com/Exercise-Type-Diabetes-exercise-frustrating/dp/B0BYGNFQ47*Links to Ginger's articles on Beyond Type 1: https://beyondtype1.org/ginger-vieira-freelancer/*The articles referenced in the episode are as follows:https://t1dexchange.org/semaglutide-type-1-diabetes/https://beyondtype1.org/mounjaro-results-obesity-type-2-diabetes/https://beyondtype1.org/over-treating-low-blood-sugars/

In this episode, Jesse and Lindsey talk about how Type 1s can move beyond their core type patterns by incorporating tools from Type 4 and Type 7. Raising Boys and Girls, David Thomas, from Daystar Counseling joins the show and shares how he came to realize he was a Type 1 and the ways he uses tools from other types in his life and counseling practice. LEAVE A REVIEW FOR "HOW WE RELATE" ON... Amazon: www.amazon.com/How-We-Relate-Und…1687805660&sr=8-1 GoodReads: www.goodreads.com/book/show/60693284-how-we-relate Barnes & Noble: www.barnesandnoble.com/w/how-we-rela…ks/1141293005 Target: www.target.com/p/how-we-relate-b…over/-/A-86919825

IG: @taratalksfood TikTok: @tarastestkitchen  LinkedIn: https://www.linkedin.com/in/taraasmith/     T ‘ A R A   S M I T H, MS Director of Beyond Type 2 | Beyond Type 2 She/Her/Hers | 650.924.5959 | beyondtype2.org FACEBOOK / TWITTER / INSTAGRAM / LINKEDIN / YOUTUBE    

https://donate.beyondtype1.org/fundraiser/4139638 “In 1995, at 12, I was diagnosed with Type 1 Diabetes. After surviving Spinal Meningitis as an infant and a neat fatal asthma attack, I couldn't believe I now had T1D. I was told I'd never be like other people, I wouldn't live past the age of 21. Now turning 40 this year, I've always proved wrong with what I've accomplished in this crazy life. From raising over $8,000 for Diabetes research through becoming the first T1D female MMA fighter in the country, the first T1D MMA fighter in New England. Now I'm doing something I never thought I'd do! Join 49 other inspiring Type 1 Diabetics as we race in the New York City Marathon to raise awareness and money for Beyond Type 1! It won't be easy, but nothing in my life has been. I believe we can hit over $3,000.00 to fight Type 1! Please help me support Beyond Type 1 by donating through my page. The process is fast, easy, and secure. Thanks so much for your support... and please remember to send this page to any friends you think might be interested in donating!” BJ Garceau Being a healthcare provider and cannabis connoisseur, a decade of weed, being a budtender, festivals, mushrooms helping depression, accessible micro dosing, the medical benefits of mushrooms, mushrooms and munchies, Triscuits and hummus, type 1 diabetes, meningitis, a vegan and gluten-free life, vegan s'mores, the New York Marathon, micro tripping, feeling free, Level MD's social media presence, everything else is frosting, the Adventure Zone, asthma, traumatic health concerns, living with a chronic illness, technology across time, karate, autoimmune disorders, micro-dosing edibles for arthritis, Advair, not getting to do karate, brain hands communication, kickboxing, jujitsu, Mai tai, self-defense, ADHD and PTSD, Float tanks for circulation, hitting and punching things, and more! --- Send in a voice message: https://podcasters.spotify.com/pod/show/potluckypodcast/message Support this podcast: https://podcasters.spotify.com/pod/show/potluckypodcast/support

Ginger is always on the cutting edge of diabetes management and I'm thrilled to have her back on the podcast! She's been T1D since 1999 and has been writing about diabetes related topics for 15 years. Ginger has authored or co-authored 5 books relating to diabetes and she's currently a writer for Beyond Type 1 and Beyond Type 2. She has a new book coming out in March about exercise and T1D - can't wait to read it!Today, Ginger and I are talking about using Metformin and/or Ozempic to improve insulin sensitivity in people with Type 1 diabetes. She wrote a very comprehensive article about her experiences with Metformin, published in September 2022 (linked below). At that point, she had five months worth of data under her belt. Recently, she began to enhance her diabetes management with weekly injections of.Ozempic (newly published article on this subject linked in show notes). We talk in depth about why Metformin is effective in improving insulin sensitivity and how it helps to compensate for other hormonal deficits in people with Type 1 diabetes. This episode is jam-packed with important information that you won't find anywhere else - don't miss it!Original July 13, 2022 episode: https://podcasts.apple.com/us/podcast/the-fast-life-with-diabetes-intermittent-fasting/id1601043790?i=1000569738289https://stream.redcircle.com/episodes/bbbb4e6f-eff9-4df4-bac4-723737afd00f/stream.mp3*Check out her website for links to her books and the articles she has written.https://www.gingervieira.com*Find her on Twitter at @GingerVieira*Links to Ginger's articles on Beyond Type 1: https://beyondtype1.org/ginger-vieira-freelancer/*The articles referenced in the episode are as follows:https://beyondtype1.org/taking-metformin-type-1-diabetes/https://t1dexchange.org/semaglutide-type-1-diabetes/

Beyond Type 1 is a global leader in the diabetes community with trustworthy resources on all aspects of diabetes, including healthcare. Julia Flaherty is a content manager at Beyond Type 1 with 20 years of experience living with type 1 diabetes. She's faced her share of frustrations navigating healthcare and is here to share valuable information and resources that help address the pain points people with diabetes experience when it comes to healthcare coverage.Resources:Beyond Type 1: beyondtype1.orgBeyond Type 2: beyondtype2.org(Blog) Health Insurance 101: Selecting The Right Plan For Managing Type 2 DiabetesSuite of T1D  insurance resources: https://beyondtype1.org/insurance-type-1-diabetesSuite of T2D insurance resources: https://beyondtype2.org/insurance-type-2-diabetesHealthcare glossary: https://beyondtype1.org/healthcare-glossaryInsulin affordability resources: www.Getinsulin.orgBeyond Type 1 Mental health resources: https://beyondtype1.org/mental-healthBeyond Type 2 mental health resources: https://beyondtype2.org/mental-healthHaving Healthcare Cost Conversations to Improve Patient Outcomes: A Practical Guide: https://www.diabeteseducator.org/news/perspectives/adces-blog-details/adces-perspectives-on-diabetes-care/2022/02/07/cost-conversations-to-improve-outcomes

Running a marathon is an accomplishment for anyone but running a marathon with type 1 diabetes on board is especially awe inspiring! Today my guest is Falyn Shilts. Falyn is a type 1 warrior who was diagnosed as a teen. She's now is a mother of four who is crushing her goal of proving to herself and to the world that, even with type 1 diabetes, she can do anything. Listen in as I get to interview Falyn before and then after she runs the New York City Marathon as part of the Beyond Type 1 team! Also, check out the links below to find Falyn on Social Media. She's a fun follow!  FINDING FALYN ON SOCIAL MEDIA and the WEBFalyn's LinktreeFalyn on InstagramFalyn on FacebookSupport the showFollow the show on Instagram @sugarmamaspodcastCome join the Facebook Group!Visit the Sugar Mama's Podcast WebsiteDonate to the show through Buy Me a Coffee!

On November 6, 2022, a team of 50 living with type 1 diabetes will race through the five boroughs of NYC and show the world what living beyond type 1 looks like Vince Carter Bellingham WA  and Harry Sills Edmonds WA,  talk about their journey from diagnosis to running a marathon. Type 1 diabetes is a chronic autoimmune condition that makes the body unable to produce insulin, the hormone that regulates blood sugar. Without insulin, our bodies cannot use the sugar in our bloodstream as energy, causing people to experience diabetic ketoacidosis (DKA) or worse complications, including death. If an individual goes undiagnosed or is misdiagnosed, these life-threatening complications become a reality. This is why recognizing the early symptoms of type 1 diabetes is critical. Symptoms may develop rapidly and can be mistaken for the flu or other illnesses and a delayed diagnosis can have serious consequences.

We caught Jane K. Dickinson PhD, RN, CDCES at ADCES22 in Baltimore, MD after she finished hosting a panel discussion. The panel showcased Julie K. Heverly at the DiaTribe Foundation, Mary Jane Roche from the College Diabetes Network, and T'ara Smith from Beyond Type 1. All three are individuals live with diabetes and took the stage to share their perspectives and experiences with DCESs. Jane joins us today to share the highlights of that discussion, along with some insights into how the DCES and other healthcare professionals can further support the needs of their patients.ResourcesADCES22 On-Demand Session available until October 24, 2022 at ADCES22.org. 

It's in the news! The top stories and headlines around the diabetes community this week include: A new way to sneak islet cells into the body without needing immunosuppressive drugs, routinely checking young children for T1D markets before symptoms show up, a non invasive way to measure blood glucose uses Radio Frequency, a DIY movement publishes in the New England Journal of Medicine and more! Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! *Click here to learn more about OMNIPOD* *Click here to learn more about AFREZZA* *Click here to learn more about DEXCOM* Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and these are the top diabetes stories and headlines of the past seven days. XX In the news is brought to you by T1D Exchange! T1D Exchange is a nonprofit organization dedicated to improving outcomes for the entire T1D population. https://t1dexchange.org/stacey/ XX French biopharma company Adocia has established a first proof of concept for its AdoShell Islets implant. This was in rats.. but they achieved glycemic control without insulin injections and without immunosuppressive drugs for four months. AdoShell Islets is an immuno-protective synthetic biomaterial that secrets insulin in response to blood glucose levels. The physical barrier formed by the AdoShell biomaterial allows the implanted cells to be invisible to the host's immune system while allowing the necessary physiological exchanges to occur for the survival and function of the islets. These researchers are optimistic that their unique approach can be translated from one species to another. https://www.labiotech.eu/trends-news/adocia-implants-diabetes/ XX Can starting a closed loop system right away help keep kids with type 1 in the honeymoon stage longer? New study says.. probably not. The latest findings are from the Closed Loop From Onset in Type 1 Diabetes (CLOuD) trial, a multicenter, open-label, parallel-group, randomized study, published online September 7 in the New England Journal of Medicine by Charlotte K. Boughton, PhD, and colleagues. In CLOuD, 97 youths aged 10-17 years were randomized to hybrid closed-loop therapy or standard insulin therapy (control) within 21 days of type 1 diabetes diagnosis. I found this a bit confusing, in the standard insulin therapy groups, participants could switch to insulin pump therapy or use flash or continuous glucose monitoring (CGM) or approved closed-loop systems if clinically indicated. So this isn't comparing an AID system to MDI. At 12 months, there were no differences after a mixed-meal tolerance test, with levels declining in both groups and dropping further by 24 months. Interestingly, they said glycemic control didn't differ significantly between the two groups. https://www.medscape.com/viewarticle/980356 XX Moving closer to a non-invasive way to measure blood glucose. The GlucoRx BioXensor uses radio frequency technology alongside a multiple sensor approach to measure blood glucose levels every minute. This looks to be about the size of a Libre 3 or Dexcom G7.. It's said to have smart alarms and remote monitoring capability and just sticks on the skin. The MARD is 10 point 4, which is less accurate than CGMs on the market now, but much better than any other noninvasive device to make it this far. In addition to measuring blood glucose the makers say it can measure oxygen levels, ECG, respiration rate, heart rate, temperature, activity, sleep, and early fall detection. Pivotal clinical study later this year and then the say they'll submit for European approval. https://www.med-technews.com/news/latest-medtech-news/glucorx-and-cardiff-university-to-bring-out-non-invasive-con/ XX RESEARCHERS in Oxford have launched the first UK study in the general population to test for early markers of type 1 diabetes, before children develop symptoms or need insulin. They're offering a finger stick test when children have their pre-school vaccination. Very small start, only 60 kids, but these researchers say with a recent, more accurate test to check for markers early on, they hope to find more children before DKA sets in. https://www.oxfordmail.co.uk/news/20977659.oxford-scientists-launch-study-early-markers-type-1-diabetes-children/ XX The first Randomized Controlled Trial on open source automated insulin delivery (AID) is now published in a peer-reviewed medical journal. Big news for and from the we are not waiting crowd. The CREATE Trial evaluated the efficacy and safety of an open-source system using the OpenAPS algorithm in a modified version of AndroidAPS. This study included children and adults and found that across all ages, time in range was 14 percent higher than those who used commercial hybrid closed loop systems. There's more to it, and I”ll link it up, but this study concluded that a widely used open-source AID solution, works and is safe. Congrats to Dana Lewis and all the researchers involved. https://diyps.org/2022/09/07/nejm-publishes-rct-on-open-source-automated-insulin-delivery-openaps-algorithm-in-androidaps-in-the-create-trial/ XX Back to the news in a moment but first.. The T1D Exchange Registry is a research study conducted online over time, designed to foster innovation and improve the lives of people with T1D. The platform is open to both adults and children with T1D living in the U.S. Personal information remains confidential and participation is fully voluntary. Once enrolled, participants will complete annual surveys and have the opportunity to sign up for other studies on specific topics related to T1D. The registry aims to improve knowledge of T1D, accelerate the discovery and development of new treatments and technologies, and generate evidence to support policy or insurance changes that help the T1D community. By sharing opinions, experiences and data, patients can help advance meaningful T1D treatment, care and policy. The registry is now available on the T1D Exchange website and is simple to navigate, mobile and user-friendly. For more information or to register, go to www.t1dregistry.org/stacey XX Medtronic is waiting for FDA clearing of the new 780G.. already approved in Europe. New study results published in The Lancet Diabetes & Endocrinology, Medtronic announced Thursday put the AID pump up against multiple daily injections plus CGM. Small study, 82 people, all with an A1C over 8. After using the 780G for six months, the group saw a reduction of 1.4 percent in their levels with a quarter of that group dropping their A1C below 7. None of the MDI group dropped to that level. Time in range saw most improvement overnight. The MiniMed 780G system has been cleared in Europe since 2020. Medtronic submitted it to the FDA for U.S. approval in the spring of 2021 but is still awaiting a decision, slowed down by the roadblocks caused by a late 2021 warning letter from the agency that called out quality control issues at the California headquarters of its diabetes business. https://www.fiercebiotech.com/medtech/medtronics-new-minimed-insulin-pump-adds-27-boost-time-range-study-finds XX Change at one of the top posts at Dexcom. Jake Leach moves from Chief Technology Officer to Chief operating officer. He's been at the company since 2004 to work on the first commercial Dexcom CGM system. He's been a frequent guest of the show and we hope that continues. https://www.businesswire.com/news/home/20220831005236/en/DexCom-Promotes-Jake-Leach-to-Chief-Operating-Officer XX Next week we're looking ahead to the New York City Marthong. Beyond Type 1 puts together a gret team each year and I'm taking to one of the runners. He's also nabbed a spot in the world series of poker – which do you think is tougher on his type 1 diabetes? This past episode is all about Omnipod 5 – a panel of people who've sued it for a few weeks now.. and the director of medical affairs to answer your questions. Listen wherever you get your podcasts That's In the News for this week.. if you like it, please share it! Thanks for joining me! See you back here soon.

A fascinating interview with Meaghan Bates Lorenz, about parenting a child with Type-1 Diabetes. We are grateful for this candid discussion in which Meaghan  shares the things we all need to know about Type-1 Diabetes. Listen in and learn something new!   Websites that are wonderful all-around resources: Beyond Type 1  T1D Exchange DiaTribe Facebook support groups: T1D Mod Squad Diapers and Diabetes Facebook groups that support the type of insulin pump and CGM you use if you use them- there are support groups for each brand and they are incredibly helpful. Books: Sugar Surfing Dr. Bernstein's Diabetes Solution Think Like a Pancreas Resource for getting affordable insulin: GetInsulin.org DiaTribe Article and Resources for Insulin For activism about the extreme costs of insulin. I recommend contacting your Senator to demand that insulin not only be capped but BE FREE. It is a life-saving medicine and it should cost nothing, just as it does in so many other countries around the world. Resources for Allies who want to learn more about what life with Type 1 is like: Stories about Diabetes Virtual Diabetes Coaching taught by professionally trained Type 1 Diabetics: Integrated Diabetes Services

It's in the news! The top stories and headlines around the diabetes community this week include new progress in the quest for oral insulin to treat type 1, a new study says a common type 2 diabetes drug may help those with serious heart condition, a look at teen brains and T1D, NSAID and type 2 and more! Learn about the T1d Exchange: www.t1dexchange.org/stacey  Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here ----- Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners! ----- Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! *Click here to learn more about OMNIPOD* *Click here to learn more about AFREZZA* *Click here to learn more about DEXCOM* Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and these are the top diabetes stories and headlines of the past seven days. XX In the news is brought to you by T1D Exchange! T1D Exchange is a nonprofit organization dedicated to improving outcomes for the entire T1D population. https://t1dexchange.org/stacey/ XX Our top story.. very early on here, but some progress in oral insulin for type 1. A team at University of British Columbia has developed a different kind of tablet that isn't made for swallowing, but instead dissolves when placed between the gum and cheek. This method delivered all the insulin to the liver without wasting or decomposing any insulin along the way. That's a big change from earlier studies and methods. The oral tablets absorb after about half an hour and last for up to four hours.. long way to go, no human trials yet. The the lead researcher on this project has a father with type 1 . https://www.sciencedaily.com/releases/2022/08/220830093215.htm?fbclid=IwAR1AzjI5UJma9I6g4hST044FS0MbJnUA0EXCmKXyhcOiOKL-ckIQTO4h8dY XX The type 2 diabetes drug dapagliflozin might also be used to help people with heart failure. A new study at Brigham and Women's Hospital showed that dapagliflozin – sold under the brand name Farxiga - reduced the risk of a cardiovascular death, or worsening heart failure, regardless of ejection fraction. Ejection fraction is a term that basically refers to how much blood is pumped out by the left ventricle of the heart each time it contracts. That's important because this drug has already been shown to help people who have the reduced pumping. And that's a lot more people. Big study here, more than 12-thousand people with lots of ages and races, benefits consistent throughout. https://www.bostonglobe.com/2022/08/29/business/brigham-womens-researchers-say-diabetes-drug-helps-reduce-heart-failure/ XX I hesitate to bring this study up, but it's gotten a lot of attention this week. It shows tight control of blood sugar in teens with Type 1 diabetes may help reduce the disease's damaging effects on the brain. But this small study from Nemours Children's Health, Jacksonville and Stanford University School of Medicine didn't release any numbers, n other words, it's not clear what they mean by tight control or at what level they're referring to for brain issues. Their findings to indicate that automated hybrid closed loop systems work really well and that better glucose control can actually improve brain structure and function in teens with type 1. I've reached out to this group and we're working on getting more information in a future episode. https://neurosciencenews.com/blood-sugar-brain-diabetes-21328/ XX Very early on here.. but an Indiana startup says they have a potentially game changing type 1 drug in development. In T1D, the body's immune system causes destruction of beta cells, and as a result, they eventually stop producing insulin. These researchers say their models show thy can take what were thought to be dead beta cells, which are actually sleeping beta cells, and increase their insulin secretion and, basically, get them back to a functional state.” They're focusing on a calcium imbalance within the beta cell and designing molecules to correct that calcium imbalance, ultimately returning the pancreas to a healthy state. JDRF has given them a big grant for a two year project, hopefully getting them to clinical trials. https://www.insideindianabusiness.com/articles/startup-awarded-nearly-1m-to-advance-diabetes-drug XX People with type 2 diabetes might face a substantially increased risk of heart failure if they take ibuprofen or some other type of nonsteroidal anti-inflammatory drug (NSAID), accord to a new Danish study. Short-term NSAID use increased risk of hospitalization for heart failure by 43% in people with type 2 but no previous heart problems. This was a large but preliminary study presented at the European Society of Cardiology's annual meeting. NSAIDs increased the risk of heart failure even more in type 2 diabetics who were 80 or older (78%) or who had high blood sugar levels (68%), the results showed. Those who'd never used an NSAID before had the worst reaction, with their heart failure risk nearly tripling. Type 2 diabetics should consult with their doctor before taking any pain medicine, the doctors said. Other types of pain meds -- specifically acetaminophen (Tylenol) -- should be safe for them to use. https://www.usnews.com/news/health-news/articles/2022-08-24/certain-painkillers-raise-heart-failure-risk-in-people-with-type-2-diabetes XX Back to the news in a moment but first.. The T1D Exchange Registry is a research study conducted online over time, designed to foster innovation and improve the lives of people with T1D. The platform is open to both adults and children with T1D living in the U.S. Personal information remains confidential and participation is fully voluntary. Once enrolled, participants will complete annual surveys and have the opportunity to sign up for other studies on specific topics related to T1D. The registry aims to improve knowledge of T1D, accelerate the discovery and development of new treatments and technologies, and generate evidence to support policy or insurance changes that help the T1D community. By sharing opinions, experiences and data, patients can help advance meaningful T1D treatment, care and policy. The registry is now available on the T1D Exchange website and is simple to navigate, mobile and user-friendly. For more information or to register, go to www.t1dregistry.org/stacey XX We told you about The Human Trial, Watch this gripping new documentary about the brave men and women who volunteer to test a radical new treatment for type 1 diabetes. n 2011, Lisa Hepner and her husband Guy Mossman heard about a radical stem cell treatment for diabetes, a disease that shockingly kills more than five million people each year. Driven by a desire to cure Lisa of her own type 1 diabetes (T1D), the filmmakers were given unprecedented, real-time access to a clinical trial — only the sixth-ever embryonic stem cell trial in the world. What follows is an intimate journey with the patients and scientists who put themselves on the line to be first. Now, in partnership with Beyond Type 1 & JDRF , they're offering the film for free. You are urged to make a donation to JDRF when you click over, there is an option to select zero, https://watch.showandtell.film/watch/the-human-trial-beyond-type-1 XX Next week we've got a great episode all about Omnipod 5 in the real world. I spoke to a panel of moms and a young adult using the system. And we've got Insulet's Director of Medical affairs addressing the questions that come up. This past episode is with my son Benny, talking about what it was like to spend 8 weeks away at non diabetes camp without any remote monitoring from us. Listen wherever you get your podcasts That's In the News for this week.. if you like it, please share it! Thanks for joining me! See you back here soon.

Today's episode is all about Afrezza, the inhaled insulin! My Guest today is Ginger Vieira. Ginger is the Senior Content Manager at Beyond Type 1 and Beyond Type 2 and has been living with T1D since she was in middle school.  She is a WEALTH of diabetes knowledge. Be sure to check below for links to all her diabetes resources including all of the books she has written! At the moment, Afrezza is only FDA approved for people who are 18 years and older BUT, AS WE SPEAK, there is a clinical research trial being done to see if it is safe and effective in the pediatric population. After listening to this episode you are going to want them to hurry and and get that study DONE so our kids will have access to this amazing drug. I will put a link below to the trial as well. Enjoy! HELP SUPPORT THE SHOWFollow the show on Instagram @sugarmamaspodcastCome join the Facebook Group!Visit the Sugar Mama's Podcast WebsiteWrite a Review and help other type 1 families find the show!Donate to the show through Buy Me a Coffee!**Buy me a Coffee is a no strings attached way to support the show! Every donation given, whether it is a one time gift or a monthly membership, goes to making this podcast come to life each and every week. It helps fund things like the physical and virtual equipment needed to produce a podcast such as a website (I use Podpage), a recording platform (I use Squadcast), a podcast hosting platform (I use Buzzsprout) and editing software ( I use Descript). I truly appreciate support from listeners like you so, from the very bottom of my insulin cartridge, thank you!OTHER INFO MENTIONED IN THE SHOWGinger on Instagram   Find all of Ginger's books and resources HEREThe Pediatric Afrezza Clinical Research TrialSupport the show

Get caught up on the news and headlines around the diabetes community! The top stories in the last seven days: Senate Republicans nixed an insulin copay cap, but Democrats say they will revisit this issue in a few weeks, Dexcom pushed back their G7 timeline in the USA after the FDA asks for changes, once weekly basal insulin moves forward in trials. Plus, Beyond Type 1 is back in the NYC Marathon and much more! Learn more about the T1D Exchange: https://t1dexchange.org/stacey/ Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here ----- Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners! ----- Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! *Click here to learn more about OMNIPOD* *Click here to learn more about AFREZZA* *Click here to learn more about DEXCOM*   Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and these are the top diabetes stories and headlines of the past seven days. XX In the news is brought to you by T1D Exchange! T1D Exchange is a nonprofit organization dedicated to improving outcomes for the entire T1D population. https://t1dexchange.org/stacey/ XX The copay cap on insulin may come back before the Senate in a few weeks. Senate Majority Leader Charles Schumer say he'll bring tht issue back up.. after Republicans blocked it in a sweeping climate, inflation and health care package passed by the Senate on Monday. Speaking on MSNBC's “The Rachel Maddow Show.” Schumer said, “We're going to come back and make them vote on that again.” Seven Republicans still voted with all 50 Democrats, three short of the 60 votes needed, and it is possible more Republicans would support it if it came up as a standalone measure. It's not clear if this would again be a copay cap or in fact a cap on the actual price of insulin for all, including the uninsured. https://thehill.com/policy/healthcare/3594003-schumer-senate-will-vote-again-on-35-insulin-cap-after-gop-blocked-it/ XX Dexcom is pushing back the timeline for a U.S. launch the G7. That's after the FDA raised questions about the device's software during a review. This has something to do with how the G7 and it's smartphone apps deliver alarms to users. Looks like maybe a limited release in the 4th quarter of this year and full rollout in 2023 if there aren't any other hiccups. As you likely know, the G7 is nearly 60-percent smaller than the G6, it's transmitter and sensor all in one and has a much shorter warmup period. It's been approved in Europe since March. https://www.fiercebiotech.com/medtech/dexcom-resubmit-g7-glucose-monitor-software-fda-review-pushing-back-us-launch XX One type of once-a-week basal insulin gets the go ahead to move forward with clinical trials in the US. Gan & Lee Pharmaceuticals says it's investigation drug called GZR4 is more stable with less day to day variation than once a day basal insulin. There are a few of these weekly insulins in trials, none yet approved. Gan & Lee is also doing trials of the drug in China where they are already a big player in the insulin market. https://www.ganlee.com/detail/668.html XX XX Good news for Senseonics, makers of the Eversense implantable CGM. Shares were up on second quarter earnings and future expectations. I don't generally report on stock market moves of diabetes companies, but the past few years have been a bit iffy for Senseonics and there was speculation on whether this CGM option might not be available in the US. They partnered with Ascensia Diabetes Care and got the six month approval for Eversense earlier this year. https://www.massdevice.com/senseonics-stock-q2-2022/ XX A new call for comments to the FDA but the deadline is TODAY august 15 at midnight eastern time. I'm going to read directly from a post by Joanne Milo in the CGM in the Cloud off topic group. Joanne's been a guest of the show and leads the loop and learn group – she writes. “We have until August 15, 2022 to provide comments on FDA changes to the way CGM display and alarm systems are regulated. This has implications for remote monitoring and automated insulin delivery systems, both commercial and DIY. We request your assistance in helping the FDA and device providers (FDA considers software for treatment of disease to be a device) understand the benefits of real-time CGM access and the risks we carry by not having ubiquitous real-time access to our diabetes device data. We hope you will choose to spend a moment to add your voice to the #WeAreNotWaiting chorus. They provide some text which I'll link up in the show notes as well as the links to this post and the FDA comment portal. https://www.regulations.gov/commenton/FDA-2018-N-1910-0047?fbclid=IwAR2WAtGl3vjTUonamNdlBtAu_pg2-xQOVy8bSqG2peLCUz2eq8R8OgLqtHQ https://www.facebook.com/groups/CGMITCOFFTOPIC XX The T1D Exchange Registry is a research study conducted online over time, designed to foster innovation and improve the lives of people with T1D. The platform is open to both adults and children with T1D living in the U.S. Personal information remains confidential and participation is fully voluntary. Once enrolled, participants will complete annual surveys and have the opportunity to sign up for other studies on specific topics related to T1D. The registry aims to improve knowledge of T1D, accelerate the discovery and development of new treatments and technologies, and generate evidence to support policy or insurance changes that help the T1D community. By sharing opinions, experiences and data, patients can help advance meaningful T1D treatment, care and policy. The registry is now available on the T1D Exchange website and is simple to navigate, mobile and user-friendly. For more information or to register, go to www.t1dregistry.org/stacey XX Team of 50 individuals living with type 1 diabetes will raise awareness and funds for their chronic illness SAN MATEO, Calif., (Aug. 3, 2022) – Going the extra mile this year, global diabetes nonprofit Beyond Type 1 was named an Official Charity Partner for the 2022 TCS New York City Marathon, taking place on November 6. Beyond Type 1 will be among the 500 official charity partners providing thousands of runners the opportunity to run in the world's most popular marathon. This year's Beyond Type Run team includes nearly 50 runners across the United States, Canada, Ecuador and Australia, who are raising awareness and funds for type 1 diabetes as ambassadors for Beyond Type 1, showcasing how they live beyond their diagnoses and supporting crucial efforts and programs for others affected by this condition. First-time Marathon Runner Kyle Banks, known for his tour with the Broadway cast of The Lion King, is the team captain. “The Beyond Type Run team displays the ultimate resilience and strength as they run the marathon. If it weren't for the team jerseys or the technology attached to their bodies, you'd never know they were living with a chronic illness,” said Beyond Type 1 CEO Deborah Dugan. “We are grateful to them for helping us raise awareness, and we thank all of our sponsors for their generous support and donations to the team.” Since 2017, Beyond Type 1 has had roughly 150 people with type 1 diabetes run the TCS New York City Marathon through the New York Road Runners (NYRR) Official Charity Partner Program. “The TCS New York City Marathon serves as one of the world's largest fundraising platforms supporting hundreds of charities and philanthropic efforts,” said Christine Burke, Senior VP of Strategic Partnerships, NYRR. “We are very proud to support Beyond Type 1 and the incredible impact they have made to the diabetes community as they raise important funds to support people with diabetes.” The NYRR Official Charity Partner Program offers an opportunity for nonprofit organizations to raise funds to support their missions and services. Participating charities can offer guaranteed entry to runners who fundraise on their behalf. Since its inception in 2006, the TCS New York City Marathon Official Charity Partner Program has raised more than $400 million for more than 1,000 worthy nonprofit organizations across the globe. Prior to the start of the official program, the New York City Marathon had served as an outlet for individual philanthropic runners since the 1980s. https://beyondtype1.org/beyond-type-1-nyc-marathon-2022/ XX Morgan Shepard book Morgan Shepherd So happy to announce my book “ T1D Looks Like Us! A Type 1 Diabetes Story” is now available to order! I am so excited to share this piece of my heart with you ❤️ Rose was diagnosed with Type 1 Diabetes (T1D) when she was seven years old. Now she is nine and at times feels lonely because she doesn't know any other kids with T1D. With help from her mom, Rose meets people from all over the world who also live with T1D and have their own unique stories to share! This book is intended to spark conversations about empathy, differences, and self-compassion. Through the text children will learn not only about Type 1 Diabetes but also about the diversity of people who are living bravely with T1D. The book is perfect for newly diagnosed children, siblings, and classrooms that have a student living with T1D. XX Next week I'm talking to the folks at Patients For Affordable Drugs about the bill that passed the Senate this week. The insulin copay cap was removed, but what does it really mean for medication prices? The episode out right now is our special 500th episode where I'm interviewed by news anchor Cristina Frank, who hosts the morning show at WMTW in Maine lives with type 1. Listen wherever you get your podcasts That's In the News for this week.. if you like it, please share it! Thanks for joining me! See you back here soon.

Mentioned in this Episode and Bridget's Recommendations: Glooko Bloghttps://glooko.com/healthy-summer-eating-tips-glooko-dietician/ Nonprofit organization with a focus on education, advocacy and the pathway to cures for Type 1 diabeteshttps://beyondtype1.org Program of the nonprofit organization Beyond Type 1https://beyondtype2.org Support and management in diabetes self-care through education and outdoor adventure pursuits (based in Canada but offer virtual events and adult camps in the US)https://www.connectedinmotion.ca Nonprofit organization to end health disparities and representation for people with diabetes-https://www.diversityindiabetes.org/ (hosts free monthly support calls) Diabetes educator, Diana Mesa, RD/LDN, CDCES -https://instagram.com/enlamesanutrition?igshid=YmMyMTA2M2Y= For more on Bridget Wood, you can follow her on Instagram @ balancedwithbridgetwood and through the Glooko website https://glooko.com/. For more on Argavan Nilforoush, be sure to follow her on Instagram @babystepsnutrition, on Facebook: Baby Steps Nutrition page, on Twitter @argavanRDN, on LinkedIn @ArgavanNilforoush and through her website www.babystepsnutrition.com.

I am so excited for you to hear this episode with Ginger! Ginger has a wealth of knowledge pertaining to all things diabetes. She's been T1D since 1999 and has been writing about diabetes related topics for 15 years. Ginger has authored or co-authored 5 books relating to diabetes and she's currently a full-time writer and Content Manager for Beyond Type 1 and Beyond Type 2. Ginger has been doing intermittent fasting for 8 years and has a learned quite a bit about how fasting affects her body. Also, Ginger has spent a lot of time figuring out how to exercise while maintaining stable BGs (spoiler alert: fasting plays a major part in this!)Ginger was a fascinating guest!*Check out her website for links to her books and the articles she has written.https://www.gingervieira.com*Find her on Twitter at @GingerVieira*Links to Ginger's articles on Beyond Type 1: https://beyondtype1.org/leadership/ginger-vieira/*The articles referenced in the episode are as follows:Intermittent Fasting with T1D: https://diabetesstrong.com/intermittent-fasting-type-1-diabetes/Afrezza: https://beyondtype1.org/inhaled-insulin-type-1-diabetes/

Got a few minutes? Get caught up on the top diabetes stories and headlines of the past week. The FDA approves Abbott's Freestyle Libre, Dexcom addresses reports it may buy Insulet, Ozempic becomes a TikTok trend, Diabetes Scholarships for college and more! Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here ----- Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners! ----- Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! *Click here to learn more about OMNIPOD* *Click here to learn more about AFREZZA* *Click here to learn more about DEXCOM* Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and these are the top diabetes stories and headlines of the past seven days. we go live on social media first and then All sources linked up at diabetes dash connections dot com when this airs as a podcast. XX In the news is brought to you by T1D Exchange! T1D Exchange is a nonprofit organization dedicated to improving outcomes for the entire T1D population. https://t1dexchange.org/stacey/ XX Our top story, FreeStye Libre 3 gets FDA approval. This is a 14 -day CGM, Abbot says it's smaller and thinner, about the size of two pennies stacked up. Abbott also claims Libre 3 is the most accurate 14-day CGM based on new results. It's worth noting that there isn't another 14-day CGM on the market.. Dexcom is ten days and the upcoming G7 seems to have similar accuracy. However, Libre is less expensive and they say there will be no price increase for this new model. Libre has had iCGM designation since the Libre 2 – but the FDA says it's still not allowed for use with automated insulin delivery systems. I've asked to speak with Abbott and we'll find out more about why that is and what the company plans to do if it can't integrate with insulin pumps in the US. XX Meanwhile, Dexcom pushes back on talk that it was interested in acquiring Insulet. Here's part of the quote: It is generally our policy not to comment on rumors or speculation, however, in light of recent sustained media and market speculation as well as the upcoming American Diabetes Association conference, we wish to confirm that Dexcom is not in active discussions regarding a merger transaction at this time. We do not intend to comment further on this topic and we assume no obligation to make any further announcement or disclosure should circumstances change." I'm set to talk to Dexcom's CEO at ADA and I'll definitely ask him about this, even though they say they won't comment further. I do think it's interesting they use the word “merger” and not also “acquisition” – but the stock market seems to believe them. Dexcom went up on the news. XX New information could link environmental pollution to type 1. New study from Norway says even low concentrations of such pollutants can result in cells producing less insulin. New cases in Norway have doubled in children and teens since the 1970s. This study also included samples from American kids. Overall, the researchers found a larger proportion of those with type 1 diabetes these pollutants in their blood. They also found when mice were exposed to the pollutants, insulin production went down. https://www.news-medical.net/news/20220530/Environmental-pollutants-may-be-the-reason-behind-development-of-type-1-diabetes.aspx XX Whey protein may be the next big thing for people with type 2. Drinking a pre-made shot before meals with a low dose of whey protein seems to help better control blood glucose levels. In this study, people went about their daily lives with no changes but the whey drink. Then they spent a week with no whey, all while wearing a CGM. On average, people had two hours additional per day of normal blood sugar levels compared to the week they skipped the protein drink. The researchers believe the whey slows down food in the digestive system and also stimulate hormones than help keep glucose from rising. This was a small study, but you can bet you'll be hearing a lot more follow up.. it's a simple and promising treatment. https://scitechdaily.com/just-a-small-amount-of-protein-supplement-helps-control-type-2-diabetes/ XX At least at one hospital, the pandemic showed the telemedicine and CGM use can make a big difference in kids with type 1. For the study published in BMC Pediatrics, these researchers used data from Children's Medical Center Dallas . While the number of office visits among patients decreased during the pandemic, there was no effect on disease management in this group – both glucose control and hospitalization rates were unchanged. However, the results highlighted existing disparities among patients in minority and low-income demographics. Both before and during the pandemic, Black and Hispanic patients and those without commercial insurance had worse glucose control and higher hospitalization rates. There was however a dramatic increase in CGM use by patients without commercial insurance, likely because it was then that CGM was offered to Medicaid recipients in Texas. The researchers believe the increased use of continuous glucose monitoring along with the successful implementation of telemedicine greatly contributed to preventing worse outcomes in this patient population. https://www.news-medical.net/news/20220531/Telemedicine-continuous-glucose-monitoring-helped-attenuate-COVID-19-impact-on-children-with-Type-1-diabetes.aspx XX Heads up if you take Ozempic, might want to get that prescription squared away and filled.. a quote - “unexpected increase in consumer demand” seems to have come because of a Tik Tok trend. TikTok users have been documenting their weight loss using the hashtag #ozempic, even though it's not approved for that use, only for treatment of type 2. This seems to be more of an issue in Australia and the UK. https://www.theguardian.com/australia-news/2022/may/31/shortage-of-diabetes-medication-ozempic-after-tiktok-users-promote-drug-for-weight-loss XX Right back to the news in a moment but first we've got a new sponsor. As I mentioned, The T1D Exchange Registry is an online research study, designed to harness the power of individuals with type 1 diabetes. It's a research study conducted online over time, designed to foster innovation and improve the lives of people with T1D. Personal information remains confidential and participation is fully voluntary. Once enrolled, participants will complete annual surveys and have the opportunity to sign up for other studies on specific topics related to T1D. By sharing opinions, experiences and data, patients can help advance meaningful T1D treatment, care and policy Sign up at T1DExchange.org slash Stacey (that's S-T-A-C-E-Y). XX ADA Scientific Sessions kicks off today and continues through the weekend. I have a virtual press pass and I'm sure next week's newscast will be chock full of newly released studies. My email is already full of the previews and I wish all my friends traveling to the first in person scientific sessions since I believe 2019 a safe trip. XX Congrats to the newest class of Diabetes Scholars! Beyond Type 1's program awarded over 50 scholarships to students living with Type 1 diabetes in 2022. At over $166,000 these scholarships are made possible by individual donors and partner organizations. New this year, the Lilly Diabetes Thom Scher Policy plus advocacy scholarship. Thom was the CEO of Beyond Type 1 until his sudden death last year. The Scholarship in his name is for a student with a strong background in type 1 diabetes policy and advocacy. 100% of scholarship funds donated by individuals or partners are awarded to recipients, with Beyond Type 1 absorbing all operational costs associated with the program. https://diabetesscholars.org/class-of-2022/ XX On this week's long format episode, you'll hear about Savannah Johnson's Type 1 Way Ticket. Next week, Dexcom CEO Kevin Sayer from ADA. Listen wherever you get your podcasts That's In the News for this week.. if you like it, please share it! Thanks for joining me! See you back here soon.

It's in the news! Got a few minutes? Get caught up! Top stories this week: new research that keeps beta cells safer after transplant, a new drug for type 2 also shows weight loss success, the makers of Afrezza buy a simple patch pump, Beyond Type 1 tackles mental health and diabetes and lots more! Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here ----- Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners! ----- Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! *Click here to learn more about OMNIPOD* *Click here to learn more about AFREZZA* *Click here to learn more about DEXCOM* Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and these are the top diabetes stories and headlines of the past seven days. we go live on social media first and then All sources linked up at diabetes dash connections dot com when this airs as a podcast. XX In the news is brought to you by T1D Exchange! T1D Exchange is a nonprofit organization dedicated to improving outcomes for the entire T1D population. https://t1dexchange.org/stacey/ XX Our top story, another approach to beta cell encapsulation. There are a few methods being tested to protect the transplanted cells from the body's immune system. A new and promising one seems to be a new biomaterial in the form of microgel beads. This study was in mice only but after three months the beta cells survived and maintained blood sugar levels with no rejection drugs. Interestingly, this study put the cells into the omentum, not the liver as is apparently the usual spot. I never heard of the omentum.. in case you haven't, it's a layer of tissue connecting the stomach with the other abdominal organs. It's non-vital so it's safer if any complications take place. No word on when human trials might begin here. https://newatlas.com/medical/microgel-beads-safer-path-cell-transplants-treat-diabetes/ XX FDA approval for a new injection for type 2 diabetes called Mounjaro. It's made by Eli Illy and is shown to lower blood sugar and can help patients lose weight. Existing medicines target a hormone called the glucagon-like peptide-1 that is involved in the control of blood sugar. But Mounjaro targets a second hormone, the glucose-dependent insulinotropic polypeptide, as well. It is the first medicine to target both. While not yet approved as an obesity treatment, it's performed very well in clinical trials for weight loss. One study showed it helped patients lose an average of 16 to 22 percent of their weight: That's on par with bariatric surgery https://www.statnews.com/2022/05/13/fda-approves-lilly-diabetes-drug-that-analysts-expect-to-be-a-big-seller/ XX Big deal for MannKind, the makers of Afrezza inhalable insulin. They're acquiring Zealand Pharma's wearable V-Go Insulin Delivery Device. The V-Go is a patch pump that's meant for people with type 2 – it delivers basal insulin at a set rate all day long and can give boluses only in increments of 2 units of insulin at a time, up to 36 units in 24 hours. The deal is expected to close by the end of the month. https://www.mddionline.com/diabetes/mannkind-acquires-wearable-insulin-device-zealand-pharma XX Young adults who were at risk of food insecurity had an increased incidence of diabetes 10 years later, according to the results of a study from Washington State University. Although previous research has associated food insecurity with a range of health issues, this study showed a connection over time, which could indicate a causal relationship. The investigators could not identify the exact reason for this connection, previous research has shown that food-insecure households often have diets with lower nutritional values. The study results did not indicate differences among ethnicities or races, but they also said that a limitation of the study was the number of minorities in the sample, which could be too low to show a pattern, according to investigators. The investigators plan to evaluate food insecurity risk and health issues within American Indian and Alaska Native and American Indian populations, which they said are often left out of annual reports on food insecurity. XX Beyond Type 1 has a new mental health portal.. announced as part of this Mental Health Awareness Month. The global nonprofit is partnering with BetterHelp to provide affordable mental health resources and services to its online community with two weeks of free, professional online therapy. Beyond Type 1 will continue to expand the resources available on the site.. it's not just for this month. https://beyondtype1.org/mental-health/. XX Another entry into the quest to find a non-invasive way to monitor glucose. Movano Inc reports they have – quote - successfully validated the functionality of its proprietary and patented system-on-a-chip. They say this is designed specifically for blood pressure or glucose monitoring systems. It's very early here.. they are also creating a prototype for clinical studies. But this tech got them a new patent. We're keeping an eye on these non-invasive devices – it remains to be seen if any will be accurate enough to use to dose insulin. https://www.prnewswire.com/news-releases/movano-successfully-completes-functional-testing-of-smallest-ever-custom-mmwave-sensor-designed-for-non-invasive-glucose-and-cuffless-blood-pressure-monitoring-301545710.html XX Right back to the news in a moment but first we've got a new sponsor. As I mentioned, The T1D Exchange Registry is an online research study, designed to harness the power of individuals with type 1 diabetes. It's a research study conducted online over time, designed to foster innovation and improve the lives of people with T1D. Personal information remains confidential and participation is fully voluntary. Once enrolled, participants will complete annual surveys and have the opportunity to sign up for other studies on specific topics related to T1D. By sharing opinions, experiences and data, patients can help advance meaningful T1D treatment, care and policy Sign up at T1DExchange.org slash Stacey (that's S-T-A-C-E-Y). XX Back to the news.. Big candy recall, so heads up if you use any of these for lows. It includes specific varieties of SKITTLES® Gummies, STARBURST® Gummies, and LIFE SAVERS® Gummies due to the potential presence of a very thin metal strand embedded in the gummies or loose in the bag. No illness or injuries have been reported. I'll link up the specific lot and manufacturer information. https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/mars-wrigley-confectionery-us-llc-issues-voluntary-recall-specific-varieties-skittlesr-gummies XX A college fashion design major has a unique senior project. Naomi Kinnamon spent her senior year working on a collection titled “Type 1 Of A Kind.” This series draws on her experiences as a woman with type 1 diabetes who struggles to find clothing that fits comfortably with her insulin pump. She's lived with type 1 since 6th grade and says the most difficult clothing to find were dresses and jumpsuits. So she designed her own. Kinnamon showed off her designs at SCAD – the Savannah College of Art and Design and I'll link that up in the show notes. https://www.wsav.com/now/scad-senior-designs-clothing-for-women-with-type-1-diabetes/ XX On this week's long format episode, you'll hear about the latest on the iLet Bionic Pancreas. Next week.. Mike Joyce is set to complete an incredible long-distance hiking trail. It's actually three trails – the longest in the US – he'll talk about how he does this with type 1. Listen wherever you get your podcasts That's In the News for this week.. if you like it, please share it! Thanks for joining me! See you back here soon.

It's “In the News…” Got a few minutes? Get caught up! Our top stories this week include testing a new treatment for leukemia to see if it might help with type 1, Black patients with type 1 are at higher risk of DKA, transitioning from teen care to adult care, updates on Eversense in the US and Dexcom One in the UK and front office changes at Beyond Type 1 and Vertex. Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here ----- Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners! ----- Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! *Click here to learn more about OMNIPOD* *Click here to learn more about DEXCOM* Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and these are the top diabetes stories and headlines of the past seven days. we go live on social media first and then All sources linked up at diabetes dash connections dot com when this airs as a podcast. XX The news is brought to you by The World's Worst Diabetes Mom: Real Life Stories of Parenting a Child With Type 1 Diabetes. Winner of best new non-fiction at the American Book Fest and named a Book Authority best parenting book. Available in paperback, eBook or audio book at amazon. XX Interesting look at whether a treatment for leukemia might work against type 1. Very early on here.. but AVM Biotechnology has received a grant to find out. The drug doesn't have a name yet.. it's referred to as AVM-0703 and has been shown to delay T1D in the lab. A preclinical dose-finding and mechanism of action (MOA) study in three scenarios including pre-diabetic, new-onset, and established diabetes is the first aim of the program. Those results will be used to determine the targeted dose to be used in a pivotal efficacy study for reversal of new-onset and established diabetes. It is anticipated that for patients not showing remission, AVM0703 may reinforce other immunotherapies allowing a wider range of patients to achieve insulin independence. https://www.businesswire.com/news/home/20220405005529/en/AVM-Biotechnology-Awarded-1.6-Million-Phase-II-SBIR-Grant-to-Study-AVM0703%E2%80%99s-Potential-to-Reverse-Type-1-Diabetes XX Black patients with type 1 faced a significantly higher frequency of diabetic ketoacidosis during the pandemic, and particularly during surges, researchers reported. This was a big study at several different health centers and hospitals. Researchers found there was not significant difference in the number of patients in DKA from 2019 versus 2020.. but there was a higher proportion of Black patients. The trend continued through the pandemic and again, it was significant, 48-percent versus 18 percent. Pandemic surges emphasized the disparity even more. These researchers say their work shows racial inequities in diabetes care were present before the pandemic, starkly visible during the pandemic, and will continue to persist after the pandemic -- unless we systemically root out and target racial inequities in diabetes care," https://www.medpagetoday.com/endocrinology/type1diabetes/98044 XX A new look the transition from pediatric to adult care for people with type 1 shows.. it needs improvement. This research – based on interviews with older adolescents showed many felt unprepared and dissatisfied with the transition process. Three big takeaways – the teens are aware of the changing relationship with their parents and health care teams and often want more independence than the parents are willing to give… the teens want acknowledgement that being diagnosed at different ages means they may be more or less comfortable with self-management and the third is that they think their pediatric team isn't preparing them to work with adult providers. Personally, this means a lot to me – as my son is 17 – and I'll be asking his peds endo to work with him more on this stuff in the next couple of years. https://www.healio.com/news/endocrinology/20220401/novel-programs-needed-to-improve-transition-from-pediatric-to-adult-diabetes-care XX DiabetesWise announces the launch of it's new Pro website. It's an unbranded non-biased resource created at Stanford University to help make providers more informed about diabetes devices and streamline the prescription process. We've talked about Diabetes Wise before and I'll link it up here. It's easy to feel overwhelmed by the evolving choices and providers are in the same situation. The DiabetesWise Pro website has an extensive Device Library where providers can learn about all of the FDA-approved diabetes devices on the market based on the patient's considerations. The user can compare the devices from the different manufacturers using the Compare Device tool, which displays a side-by-side analysis of the components and details of each technology, including the steps for ordering and prescribing the device. Providers can then build a comparison report of the two devices to share with their patients, colleagues, and community. Along with the Device Library, providers can receive help with ordering and prescribing the devices for their patients using the Prescription Tools feature on the website. The Prescription Tool directs the user to a guide providing accurate up-to-date information on the necessary steps for filing a prescription and ordering the device for the patient. DiabetesWise Pro has plans to update the tool to include details on the approval of devices for patients based on insurance type. DiabetesWise Pro website features for use in clinic include: 1. Device Library- Information on specific device fundamentals 2. Comparison Tool- Comprehensive tool that allows you to compare device recommendations and share with patients 3. Prescription Tool- A step-to-step guide for ordering the device and filling a prescription based on insurance type 4. Resources for providers by providers- best tips, tricks, and workarounds for diabetes technology from providers With this new resource, there have also been enhancements to the patient-facing website at DiabetesWise. Newly approved devices have been added and there are now Spanish-language versions of the Check-Up and Device Finder. https://diabeteswise.org/#/ https://providers.diabeteswise.org/#/ XX FDA approval in February, now the Eversense six-month CGM is rolling out to patients. The price is set at 99-dollars out of pocket for the first transmitter and sensor and then $100 per month for the six months of wear. The device includes a small fluorescence-based sensor, about the size of a grain of rice, which is fully embedded in the upper arm. A transmitter stuck to the skin over the sensor reads the data, transmits the information to a smartphone and provides vibration alerts for changes in blood sugar. https://www.fiercebiotech.com/medtech/ascensia-diabetes-care-launches-eversenses-6-month-cgm-system-us XX Dexcom ONE is getting a big roll out in the UK. We've talked about this a couple of times in the past.. it's the same Dexcom technology but a bit pared down and at lower cost. This news comes as the National Institute for Health and Care Excellence (NICE) announced new guidance for adults and children managing Type 1 diabetes. NICE now recommends that adults with Type 1 diabetes be offered a choice of glucose sensors. G6 is already offered there and the G7 will be as well, but this is about national health service coverage, and the Dexcom One is the only system under consideration there. https://www.businesswire.com/news/home/20220401005092/en/Dexcom-Announces-Dexcom-ONE-the-Newest-Real-Time-Continuous-Glucose-Monitoring-System-to-Its-Range-of-Scan-Free-and-Fingerprick%E2%80%A0-Free-Devices XX Some front office news around the community.. Stem cell pioneer Doug Melton is leaving Harvard to join Vertex Pharmaceuticals. Not entirely unexpected – Melton's company Semma was purchased by Vertex and they are moving ahead toward stem cell transplantation as a functional cure for type 1. This was the company that got all those headlines last fall about the cure – you remember “It worked in this one guy!” Melton is joining the company as a distinguished Vertex Fellow. Semma, by the way, was named after his two adult children who live with type 1 – Sam & Emma. https://www.statnews.com/2022/04/05/douglas-melton-noted-stem-cell-researcher-leaves-harvard-for-vertex-to-create-diabetes-treatments/ XX Beyond Type 1 names Deborah Dugan as CEO. She replaces Thom Scher who died suddenly and unexpectedly in December. Dugan was previously the CEO of RED, the not-for-profit organization founded by U-2's Bono (bah no) and Bobby Shriver to raise awareness in the fight against AIDS. Dugan, has been recognized as one of the "100 Most Powerful Women" by Forbes, "Top Woman to Help Change the World" by Elle and as a "Nelson Mandela Changemaker" https://beyondtype1.org/beyond-type-1-diabetes-deborah-dugan-ceo/ XX Congratulations to Leo and Alana Folsom who welcome a baby boy. The couple was on a recent season of the Amazing Race and after we all saw Leo's Dexcom in one of the first episodes, he came on this show to share his story. Leo lives with congenital hyperinsulinism, where the body makes too much insulin, and had almost his entire pancreas removed. He told me at the time he was amazed by the diabetes community's support. So I just wanted to say congrats to him and to Alana and help welcome baby Kitt Edwin Folsom. XX On this week's long format episode, Laurie Harper shares her story… Laurie was diagnosed as a toddler back in 1955. She's in the Joslin Medalist Study and talks about the difference this incredible group is making. Next week you'll hear from World Champion Kayaker Sage Donnely who was diagnosed with type 1 at age 3 when she'd already been kayacking for almost a year. Listen wherever you get your podcasts That's In the News for this week.. if you like it, please share it! Thanks for joining me! See you back here soon.

Nate Checketts is the Co-Founder & CEO of Rhone, a men's performance lifestyle brand founded in 2014. Prior to Rhone, Nate worked for and consulted with some of the biggest technology and entertainment properties in the world including Cisco, The National Football League, Legends, FanVision and Sport Radar. Nate is also an avid entrepreneur who founded and launched 4 companies before the age of 30, including Rhone and Mangia Technologies, whose patents were later acquired by the San Francisco 49ers. In 2020 Nate was selected by the Sports Business Journal to their 2020 list of Forty leaders under Forty. In addition to Rhone, Nate also serves as Chairman of the Board to Beyond Type 1, a non-profit dedicated to the community of those with Type 1 Diabetes. Nate graduated from Brigham Young University with a BA in Finance. He and his wife Dayna reside in Connecticut with their three young boys, Gabriel, William and Nicholas. In this episode, we chat about what it means to be a CEO in 2022, how to create an amazing family culture, and the best way to ask for help if you are struggling. Head over to kreaturesofhabit.com and enter the promo code KOHPOD20 to receive 20% off your first order.

The Good Diabetes Podcast Episode 10 Show Notes Episode 10: Going Google with Marsha and Cindy on YOUTUBE Welcome to episode 10. When you have a questions who do you ask? Your bff, your mom, you BF? No. You go to Google. According to my google search 5.6 billion searches are performed daily. Misinformation is likely to hit. In this episode Marsha and Cindy take to the internet to see what Google says about various diabetes-related topics. Today's searches: 1. "Diabetes Reversal" 2. "Can diabetes kill me?" Resources Taking Control of Your Diabetes- Don't Freak Out! 10 Things to Know if You've been Diagnosed with Type 2 Diabetes American Diabetes Association-Cardiovascular disease Beyond Type 2- Diabetes Management Disclaimer: This podcast is for informational purposes only and is not intended to be medical advice. The material discussed on this podcast, and displayed on the associated webpage, is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified healthcare provider with any questions you may have regarding a medical condition or treatment and before undertaking a new health regimen.

Today we are diving in to the world of diabetes with Julie Cunningham, RDN,  CDCES. Odds are, you know at least one person with diabetes: whether it's a friend, family member, or even yourself. In this episode, Julie explains the different types of diabetes, advice to reduce the risk of diabetes, strategies for people with diabetes, and advice for people supporting a loved one with diabetes. We hope this is a helpful introduction, and if you're looking for even more info, check out Julie's website at www.juliecunninghamrd.comAND check out Julie's NEW book: 30 Days to Tame Type 2 Diabetes***Have any follow up questions?  Want to just say hi? Email us at info@omniafit.co!Interested in what's new on Omnia Fit? Subscribe to our newsletter here!Like what you hear and want to support more shows? We appreciate it :) Click here: https://www.buymeacoffee.com/omniafit

With type 2 diabetes being so stigmatized, it can be difficult to find other people to connect with. The main reason why I started this show and my company is because I saw a gap in representation and community for those living with type 2 diabetes. Being diagnosed with it often comes with a lot of guilt and shame. It makes it hard for people to be open about their condition and share their experiences to others. That's where the Beyond Type 2 community comes it. It is a safe space to share your stories, tips, or anything else you can think of with those that understand to a degree what you're going through. I sit down with Beyond Type 2's Senior Community Manager T'ara to talk more about how it came to be.  KEY POINTS How Beyond T2 started BT2 Community The future of BT2   CONNECT WITH Beyond Type 2 https://beyondtype2.org/ Instagram: https://www.instagram.com/beyondtype2/ (https://www.instagram.com/beyondtype2/)  CHECK OUT OUR SPONSOR https://9am.health/?utm_source=digital&utm_medium=podcast&utm_campaign=hnhsponsor (9am.health) Find more at http://www.healinginhindsight.com/ (www.healinginhindsight.com) CONNECT WITH THE SHOW Instagram https://www.instagram.com/healinginhindsight/ (@healinginhindsight) https://www.facebook.com/healinginhindsight/ (Facebook.com/healinginhindsight) YouTube: https://www.youtube.com/channel/UCU5NGS16hrObu1i3Eq2C7ug/ (Healing in Hindsight™) SUPPORT THE SHOW https://www.buymeacoffee.com/healinhindsight (www.buymeacoffee.com/healinhindsight) Healing in Hindsight™ is managed by hosthttps://taylordaniele.com/ ( Taylor Daniele™) and Produced byhttps://weare8studios.com/ ( We Are 8 Studios) This podcast uses the following third-party services for analysis: Podcorn - https://podcorn.com/privacy Chartable - https://chartable.com/privacy

Beyond Type 1 in English: beyondtype1.orgBeyond Type 1 en Español: es.beyondtype1.orgBeyond Type 2 in English: beyondtype1.orgBeyond Type 2 en Español: es.beyondtype1.orgWarning signs of Type 1 campaign: https://beyondtype1.org/warning-signs-of-type-1-diabetes/Comunidades de apoyo entre pares para la diabetes (diabetes peer support communities tip sheet): https://www.diabeteseducator.org/docs/default-source/living-with-diabetes/tip-sheets/peer-support/adces-learn-connect-engage-tip-sheet-spanish-final.pdfInsulin affordability and access resources: Getinsulin.orgLearn more about peer support communities: diabeteseducator.org/peersupport.

#114: Kimberly Ross is the Founder and CEO of ORA, an acupuncture and wellness practice in the heart of New York's Noho neighborhood, bringing a highly-curated and elevated acupuncture experience to New York. After being diagnosed with Type-1 Diabetes at age 11 and struggling with health-related issues throughout the years, Kimberly finally found great relief in acupuncture 5 years ago after receiving treatment from Gabriel Sher, now ORA's Director of Acupuncture. The concept of ORA was conceived during her time at Harvard Business School, in an attempt to make acupuncture more approachable to others experiencing health issues. She started a nonprofit when she was just 14 years old called Safe-sittings, in order to provide babysitters with Type-1 Diabetes for kids with Type-1 Diabetes. Safe-sittings was acquired by Beyond Type 1 in 2016.Kim is also the daughter of real estate developer, philanthropist, and Miami Dolphins owner, Stephen Ross.Enjoy 15% off your entire purchase of any podcast merchandise with code "THANKYOU15" at www.whatfulfillsyou.comGrab a copy of the career ebook guide, The Everyday Girl's Guide to Career Success. Shop now at www.whatfulfillsyou.comLearn more about ORA at https://oraspace.com/Follow ORA on Instagram: https://www.instagram.com/oraspaceFollow the What Fulfills You? Podcast Instagram: https://www.instagram.com/whatfulfillsyouFollow Emily Elizabeth's Instagram: https://www.instagram.com/emilyeduong/Read more on the blog: https://emilyelizabeth.blog/Support this podcast at — https://redcircle.com/what-fulfills-you-podcast/exclusive-contentAdvertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy

Nate Checketts is the Co-Founder & CEO of Rhone, a men's performance lifestyle brand founded in 2014. Prior to Rhone, Nate worked for and consulted with some of the biggest technology and entertainment properties in the world including Cisco, The NFL, Legends, FanVision and Sport Radar. Nate is also an avid entrepreneur who founded and launched 4 companies before the age of 30, including Rhone and Mangia Technologies, whose patents were later acquired by the San Francisco 49ers. In 2020 Nate was selected by the Sports Business Journal to their 2020 list of Forty leaders under Forty. In addition to Rhone, Nate also serves as Chairman of the Board to Beyond Type 1, a non-profit dedicated to the community of those with Type 1 Diabetes. Nate carries himself with a calm confidence that is rooted in humility and appreciation and he is one of the most thoughtful and intentional people I've ever had the opportunity to speak with. But above it all, he is an incredible man, husband, and father and I'm so grateful for the opportunity to have him on the show. Overview of Discussion Points Bringing up the next generation of men Leading with love and leadership, not shame Ryan Holiday - “Statue of Responsibility” Nate's Childhood 3rd of 6 children brother Spencer has a very success sports podcast in Utah Nate's Dad, Dave No tactic to intentionality, sincere What made him mad - entitlement, acting better than Parents did a great job on intentionally parenting in a privileged home Nate's definition of success Living up to dad's level of success Marriage how they met the role she plays in the family Lesson from mother - “love is a verb” marriage advice - “go to bed angry” Fatherhood Favorite part of being a dad is witnessing his kids develop Discussion about not over programming kids and letting kids be kids Intentionality of coaching character development Being the person our kids see us as What Nate struggles with Inferiority complex Relaxing Self-talk What Nate wants his kids to remember about him Where to follow: Rhone Website: http://www.rhone.com (www.rhone.com) IG: @rhone Nate IG: @natechecketts LinkedIn References Ryan Holiday - Statue of Responsibility: https://ryanholiday.net/why-we-need-a-statue-of-responsibility/ (https://ryanholiday.net/why-we-need-a-statue-of-responsibility) Spencer Checketts (Nate's brother) radio show: https://podcasts.apple.com/us/podcast/the-drive-with-spence-checketts/id1476325554 (https://podcasts.apple.com/us/podcast/the-drive-with-spence-checketts/id1476325554) VestaBoard: http://www.vestaboard.com (www.vestaboard.com) EveryMan: http://www.vestaboard.com (www.vestaboard.com)